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Chronic lymphocytic leukaemia (CLL) is characterised by a progressive 
accumulation of mature CD5+CD20+CD23+ lymphocytes. Despite the remarkable 
progress in our understanding of the immunobiology of CLL, the aetiology of the 
disease remains unknown. The consensus is that CLL cells are driven by 
(auto)antigen(s) through the B cell receptor (BCR) and are regulated by a variety of 
signals received from the microenvironment, including toll-like receptors (TLR).Our 
group has previously shown that engagement of the CD180 orphan  TLR  expressed 
by approximately 60% of CLL cells, can re-wire the sIgM-mediated signalling  from 
a pro-survival pathway, involving phosphatidylinositol-4,5-bisphosphate3-kinase 
(PI3K) and protein kinase B (AKT) to the potentially pro-apoptotic pathway through 
mitogen-activated protein kinase (p38MAPK).  
However, little is known about the function of the other BCR - sIgD in CLL and its 
possible interaction with CD180. Here we studied intracellular signalling and 
apoptosis of CLL cells following sole or sequential ligation of CD180 and sIgD.  
Our data indicated that following sequential ligation of CD180 and sIgD, CLL 
samples demonstrated enhanced p38MAPK phosphorylation leading to increased 
apoptosis of CLL cells indicating synergistic relationship between CD180 and sIgD. 
To better understand the prognostic importance of CD180 expression we sought to 
determine whether CD180 and other prognostic markers such as CD38 and ZAP70 
displayed any correlation with the known cytogenetic aberrations:TP53 and DLEU1. 
Our results suggested that CLL cells with DLEU1 deletion are characterised by the 
negative expression of both, CD180 and CD38, and this might have a significance 
for CLL prognosis. 
To explain this correlation, we hypothesised that interaction of CLL cells with their 
microenvironment through TLRs leads to the expansion of leukaemic clones, in vivo, 
in lymph nodes. Our results indicated that CD180 is heterogeneously expressed in 
the paraffin tissue sections of the lymph nodes of CLL patients and its expression 
positively correlates with the expression of Ki-67.  
Our data demonstrated, that although CD180 expression and signaling might have 
negative prognostic importance in CLL due to the enhanced proliferation of 
leukaemic cells, its interaction with sIgD would re-direct leukaemic cells towards 
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Chronic lymphocytic leukaemia (CLL) is the most frequently diagnosed adult leukaemia 
in the Western world. The median age of diagnosis in USA, Europe and Australia is 
approximately 72 years with about one quarter of patients aged<65 years and 
approximately 6% less than 50 years at diagnosis.  CLL accounts for 1% of all new 
cancer cases in the UK and 37% of all leukaemia combined. In 2014 there were 3515 
new cases of CLL in the UK: 2,204 (63%) in males and 1,311 (37%) in females, giving 
a male: female ratio of around 17: 10. 2014 statistics demonstrated that there were 
seven new CLL cases for every 100,000 males in the UK and 4 for every 100,000 




Figure 1.1: Incidence of CLL in the UK 
 
Average number of New Cases per year and Age-specific Incidence rates per 100,000 Population, UK 








1.2 Epidemiology  
CLL is characterised by populational heterogeneity. Its frequency is higher in 
Caucasians from North America, Europe and Russia as compared to African males and 
females. More importantly CLL incidence rate is significantly lower in South Asian 
countries, particularly in Japan and in China (Nabhan and Rosen, 2014). In Japan age-
adjusted incidence for CLL is less than that of mantle cell-Lymphoma (Tamura et al., 
2001; Chihara et al., 2014). There is no definite explanation of this predominance, but 
genetic predisposition is implied since the difference in occurrence is observed in 
generations after migration. An extensive survey of relatives of CLL patients 
demonstrated the familial pattern with approximately 10% CLL cases depicting a family 
history of the disease. Additionally, B cells with typical immunophenotype of CLL cells 
has been detected in circulating peripheral blood of 13.5% of blood relatives of CLL 
patients with unknown mode of transmission of the disease (Kawamata et al., 2013; 
Slager and Zent, 2014). 
1.3 Pathophysiology and Diagnosis 
Five and 10-year absolute survival from initial diagnosis of CLL patients has been 
estimated in 2009-2011 as 80.4% and 64.7% respectively in USA and in UK (London 
Cancer CLL guidelines, 2015). Although with modern therapeutic approaches long-
term survival of CLL patients has significantly improved, the underlying causes and 
aethiology of the disease are still unknown. No significant association with established 
carcinogens, infection or radiation has been identified. However, some data indicate an 
increased incidence of CLL in farmers, rubber manufacturers and those working with 
organic solvents (Brown and Rushton, 2012; Polychronakis et al., 2013) (Pulte et 
al.,2016). 
CLL is clinically heterogeneous disease, characterized by accumulation of long lived 
morphologically mature, but functionally impaired CD5+ B lymphocytes in bone 
marrow, blood and lymphoid tissues. The accumulation is due to deficient apoptosis 
and extended survival of B cell (Wiernic et al., 2003; Billard, 2014). CLL cells 
proliferation occurs in microanatomical sites called proliferation centres or 
pseudofollicles (Burger et al., 2009) in bone marrow and in the lymph nodes, from 
where these cells expand into the circulation (Gradowsky et al., 2012). CLL cells are 
predominantly monoclonal with respect to both heavy and light Immunoglobulin chains 
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and gene analysis revealed the association of CLL course with Immunoglobulin gene 
rearrangement (Munoz et al., 2012; Rosenquist et al.,2017). 
The morphology of CLL cells in blood smears is consistent with small mature 
lymphocytes with a narrow border of cytoplasm, dense nucleus with coarse condensed 
nuclear chromatin with absence of distinctive nuclei, the typical features being the 
presence of smudge and smear cells. CLL bone marrow biopsy (taken rarely and not 
used for a routine diagnosis) show different infiltration patterns: nodular, interstitial, 
mixed and diffused, whereas in early clinical stages non-diffuse patterns are generally 
found (Oscier et al., 2016; Gulati et al., 2017) 
Initially most CLL cases present without specific symptoms or the patient may present 
systemic symptoms such as night sweats, tiredness, unintentional weight loss and 
symptoms of anaemia or infection. Most patients are diagnosed because of routine 
blood test that show high white blood cell (WBC) count (Mir et al., 2017). Advanced 
CLL presents itself with lymphadenopathy of cervical, axillary or marginal lymph nodes, 
hepatomegaly, mild or moderate splenomegaly, and thrombocytopenia thus leading to 
infection and bleeding and ultimately bone marrow failure. (Rodriguez et al., 2016). 
Morbidity and mortality in CLL result from secondary infections with the major cause 
being abnormal immune function either due to humoral immunodepression inherent to 
the hematologic disease or through the immunosuppressive effects of the management 
of CLL. The majority of CLL patients suffer infections with the most common immune 
defect being hypoglobulinemia rendering patients susceptible to bacterial infections 
(Nosari, 2012; Rimon et al., 2017). 
According to revised guidelines from the international workshop on CLL 2017, the 
diagnosis of CLL is based on an increase in the number of blood lymphocytes by 50% 
or more with at least 5000 lymphocytes/l of peripheral blood with a distinctive 
immunophenotype that remain for more than 3 months (Hallek, 2017). Following clinical 
and morphological evaluation of patients and peripheral blood, the clonality of these 
cells are confirmed by flow cytometry. CLL diagnosis with flow cytometry is 
straightforward and Immunophenotyping not only distinguishes B-cell from T-cell 
disorder but also identifies CLL cells as CD20+CD5+CD23+ with dim expressions of 
Immunoglobulin IgM/IgD and CD79b as compared to those found on normal B cells. 
CD23 expression allows differential diagnosis from Mantle Cell Lymphoma (MCL), 
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(Nabhan and Rosen, 2014). Other tests are also performed besides flow cytometry to 
gain an insight into prognostication and to assess the tumour burden. These are mainly 
disease staging, fluorescence in situ hybridisation (FISH), deep sequencing, mutational 
status of immunoglobulin variable heavy chain domains (IGVH), cellular and serum 
biomarkers and (rarely) bone marrow examination (Mir et al., 2017). 
1.4 Rai and Binet staging 
At the time of presentation, depending upon various clinical characteristics, CLL 
patients are categorized into stages according to the Rai (USA) and Binet (Europe) 
staging system. Rai et al, in 1975 and Binet et al in 1977 developed clinical staging 
strategy in CLL, these staging systems are still in use today as both classifications are 
based on clinical features presented at the time of initial examination. Rai and Binet 
staging systems are considered accurate means of determining the initial prognosis for 
individual patients and to determine when and whether to start treatment. Rai system 
(I) identifies five stages starting from 0 to IV, whilst Binet system (II) has three stages 
A-B-C. Rai staging (USA) revolves around lymphocytosis, lymphadenopathy, 
hepato/splenomegaly, anaemia and then thrombocytopenia. The Binet staging 
(Europe) describes symptoms according to the presence and absence of anaemia or 
thrombocytopenia with lymphadenopathy at single or multiple sites (Table 1). Typical 
median survival time for patients for Rai stage 0 – 1 and Binet A is 12 years, and these 
are low risk patients. Median survival time for Rai stage patients IV and Binet C is less 
than 3 years and they usually fall under the high-risk category. The remaining cases 












Table 1.1: Diagnostic criteria for CLL according to the National Cancer Institute (NCI) 
and International Workshop on CLL (IWCLL 1996). Both classifications reflect bulk of disease 
and extent of marrow compromise such as anaemia, thrombocytopenia. Both staging systems have been 
recognised as simple and reliable pridictors of survival. Todate the two staging systems are used for 
assessing the clinical outcome and the survival chances of the patients with CLL. 
RAI SYSTEM 
Stage  Risk  Clinical features Median 
survival (yr) 
    
0 Low             Lymphocytosis in peripheral blood and 




Intermediate Lymphocytosis with enlarged lymph 
nodes Lymphocytosis with enlarged 
spleen/liver 
6 
III High  Lymphocytosis and anaemia 
(Hgb<11g/dL) 
2 
IV Very High  Lymphocytosis and thrombocytopenia 
(platelets <100x109/L) 
0 
BINET SYSTEM    
    
A  Hgb ≥10g/dL, Plts count ≥100x109/L, 
and <3 sites involved 
> 7 
B  Hgb≥10g/dL, Plts count ≥ 100x109/L, 
and ≥3 siites involved  
< 5 
C  Hgb <10g/dL, Plts count <100x109/L, 









1.5 Prognostic biomarkers 
CLL is a heterogeneous disease with many patients showing an indolent clinical course 
that does not require treatment for many years whilst others will present with an 
aggressive and symptomatic leukaemia requiring immediate intervention (Parker, 
2011; Hallek, 2015). Based on the risk assessment and prognostication CLL cases can 
be subdivided into categories according to the clinical outcome of the disease and B 
cell biology.  
Following are some of the hallmarks of leukemia that has prognostic significance in 
CLL which includes Lymphocyte Doubling Time (LDT) Chromosomal aberrations, IGVH 
mutations, Zap-70 expression, CD38 expression, CD49d, serum markers and novel 
gene mutations 
LDT (Lymphocyte Doubling Time) 
The time period needed to double the lymphocyte count in peripheral blood is identified 
as a simple and valid parameter to assess disease progression particularly at early 
stages of the disease (Hallek, 2008, 2015, 2017). Comparison between LDT shortly 
after initial diagnosis compared with the original count of lymphocytes at the time of 
diagnosis provides distinction between slowly and rapidly progressing disease. LDT is 
calculated by linear regression and is expressed in months. A stable LDT with no 
increase or with a slow increase in lymphocyte count for more than 12 months is 
predicted as a good prognosis while patients with an unstable lymphocyte count for 
less than 12 months are shown to have an aggressive course of disease with poor 
survival rate (Scarfo et al., 2016; Molica et al., 1987, 2018). LDT is considered valuable 
for clinical management of CLL patients as it foretells progression of disease, since 
clinical prognosis cannot be predicted without proper monitoring of lymphocyte count 








Fluorescence in situ hybridisation (FISH) tests utilising fluorescent DNA probe, have 
made it possible to carry out analysis of chromosomes with metaphase banding 
techniques that has prognostic and diagnostic significance in CLL. According to Döhner 
et al, (2000), 80% of CLL patients demonstrated the presence of genetic abnormality 
within their malignant clone. These chromosomal defects are found to have an impact 
on CLL pathology as well as on the clinical characteristics and response to therapy. 
The most common aberrations stratified using FISH are based on previous studies 
(Dohner et al., 1999, 1997, 2000; Mayr et al., 2006). With regards to overall patient 
survival and predicting response to chemotherapy, the most relevant are deletion 
13q14, trisomy 12, deletion 11q23, deletion 17p13 (P53 gene) and complex karyotypes. 
13q14 deletion 
Deletion of 13q14 is the most frequently identified chromosomal abnormality found in 
55% of the CLL patients. It involves structural abnormalities with the loss of the long 
arm of choromosome 13 with different break points (Parker, 2011). Davids et al, (2015) 
suggested that 13q14 deletion is due to the loss of two functional genes within this 
region DLEU1 and DLEU2 in CLL which are involved in the regulation of tumour 
suppressor micro-RNA molecules miR-15a and miR-16-1. Although the expression of 
micro-RNA molecules is reduced in CLL patients, this does not influence the overall 
survival time and is associated with indolent course of the disease. (Puiggros, 2014; 
Rodrigues, 2016). 
Trisomy12 
Trisomy12 is the second most frequent karyotypic abnormality seen in CLL. 10- 20% 
of CLL cases exhibit three copies of chromosomes 12. The exact molecular mechanism 
by which an extra chromosome is acquired, is still unknown. However, this genetic 
aberration present itself with an atypical morphology and immunophenotype (Baliakas 
et al., 2016). Initial studies have associated trisomy 12 with aggressive clinical course 
of the disease (Dohner et al., 2000), but later studies have indicated that poor prognosis 
of trisomy 12 correlates with the presence of other genetic abnormalities such as 
NOTCH1 mutation, and hence placed it in the intermediate risk group (Puiggros, 2014; 




Deletion of the long arm of chromosome 11q is associated with poor prognosis and 
results in genomic instability in CLL patients. The deletion is frequently associated with 
the loss of ataxia telangiectasia mutated (ATM) protein which plays a vital role in 
recruiting tumour suppressor proteins towards the DNA sites and cell cycle regulation 
(Rose-Zerrili et al., 2014). The deletion often leads to failed apoptosis, therefore 
damaged cells are not adequately removed. Patients with 11q deletions express large 
and multiple lymphadenopathy with poor survival and resistance to conventional 
chemotherapy (Hernández et al., 2015). 
17p13 tumour suppressor gene P53 deletion 
17p deletion is commonly seen in approximately 7-8% of newly diagnosed cases of 
CLL. The median survival of patients with 17p (P53) deletion is 24 months only, 
irrespective of the size of P53 deletion (Stilgenbauer et al., 2002). This unfavourable 
outcome is due to the loss of genetic material encoding for P53 gene. Monoallelic 
deletion of various sized portions of the short arm of chromosome 17 results, not only 
in the deletion of P53 locus on one allele, but it also causes mutation in the remaining 
P53 allele (Yu et al., 2017). Patients harbouring only a single deletion or mutations of 
P53 are also reported to have the worst overall median survival. P53 is required in the 
cell development where it is responsible for repairing DNA cell damage and arresting 
cell cycle in G1/S phase. However, if the damage is beyond repair then P53 promptly 
induces apoptosis signals leading to the elimination of the cell (Nabhan et al., 2015). 
Since an intact P53 pathway is required for DNA repair and for the induction of 
apoptosis, CLL patients with P53 deletion demonstrate resistance to the combination 
of chemotherapeutic regimens: fludarabine-cyclophosphamide (FC) or fludarabine-
cyclophosphamide-rituximab (FCR). Thus, patients with P53 mutations or deletions are 
included in the high-risk category as they require therapy that impacts treatment 
choices (Edelmann and Gribben, 2017). 
Complex karotypes 
The presence of 3 or more abnormalities in a single genome is considered as a complex 
karyotype and is seen in alomost 20% of CLL cases. CLL patients displaying complex 
karyotypes more commonly carry P53 loss, trisomy 12 and 11q deletion (ATM) 
(Puiggros, 2014, 2017). Detection of complex karyotypes strongly correlates with the 
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worst prognosis with shorter overall survival time and progressive disease. The majority 
of CLL cases dispalying complex karyotype are with unmutated IGVH status (U-CLL, 
see below) and positive for CD38 (Malek et al., 2013; Rigolin et al., 2017). CLL patients 
with complex karyotype have been shown to have inferior outcome after treatment with 
chemo-immunotherapy (Foà et al., 2014), reduced conditioning with allogeneic stem 
cell transplant (Grieselhuber et al., 2016) and reduced response to the BTK inhibitor 
Ibrutinib (Maddocks et al., 2015). 
IGVHgenes mutations 
The mutational status of IGVH genes separates CLL patients into two distinct types of 
the disease grouped according to the shared clinical characteristics. An unmutated 
status of IGVH genes (U-CLL) correlates with the poor prognosis and shorter survival 
time (11 months) and the patients frequently present with other cytogenetic 
abnormalities, such as deletion of 11q22, 13q14, trisomy 12 and 17p13 deletion or P53 
dysfunction. In contrast, mutated IGVH genes (M-CLL) are associated with indolent 
course of the disease and longer survival time (293 months) and often present with a 
single 13q14 chromosome abnormality (Dunphy and Cherie, 2010; Pepper et al., 2012; 
Bulian et al.,2017). 
Normal B cells as well as CLL B cells from a large group of patients undergo somatic 
hypermutation (SHM) in germinal centres (GCs) of lymph nodes. Following antigenic 
stimulation through the follicullar dendritic cells and T cell signals, IGVH genes undergo 
somatic hypermutations aimed at the affinity maturation of the B cell receptor (BCR). 
Normal B cells with low affinity BCRs for antigens undergo apoptosis, while those B 
cells with high affinity for antigens preferably differentiate into plasma cells and memory 
B cell (Chiorazzi and Ferrarini, 2003; Heyman et al., 2016). In CLL, such cells are 
termed Mutated (M-CLL). However, in the second group of patients CLL B cells go 
through affinity maturation outside germinal centres without T cell signals. These cells 
exhibit low affinity maturation as no somatic mutations are introduced in IGVH regions 
therefore these cells are termed Unmutated CLL cells (U-CLL). By various estimates, 
about 50 -70% of CLL patients have M-CLL clones, and this is a widely accepted 
prognostic indicator of an indolent disease.  A further study suggested that somatic 
IGVH mutations in CLL cells influence the antibody reactivity: U-CLL cells expressed 
highly polyreactive BCRs, whilst M-CLL cells were characterised by the restricted BCR 
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reactivity (Herve et al., 2005; Hacken and Burger, 2016).They concluded that whilst 
both, M-CLL and U-CLL cells are derived from autoreactive B cell precursors, somatic 
hypermutation can be responsible for the different clinical courses in M-CLL and U-CLL 
patients. 
 
Figure 1.2. Cellular origin of mutated (M) and Unmutated (U) CLL cells via T cell 
dependent and T cell-independent B cell responses. The M-CLL cells following signals from T 
cells undergo massive proliferation in germinal centres (GC) dark zones along with somatic 
hypermutation (SHM). These cells with improved BCR affinity then enter GC light zone and interact with 
follicular dendritic cells (FDC) and helper T cell (TH Cells) and undergo class switch recombination of 
their Ig heavy chain constant region genes. These mutated cells then leave GC and differentiate into 
either plasma cells or memory B cells. U-CLL cells develop without T cell signals from a marginal zone 
(MZ). These cells do not experience any SHM and exhibit very low affinity BCRs (Kipps et al, 2016). 
 
ZAP70 expression 
Zeta associated protein kinase (70KDa, ZAP70) is a T-cell specific protein tyrosine 
kinase and its expression in CLL cells is considered to be a negative prognostic 
indicator. Intracellular ZAP70 expression exhibits a significant correlation with U-CLL, 
and the patients are characterised by poor overall survival rate (Rossi et al., 2010; 
Gomes et al., 2017). 
Normal mature B cells use Syk protein kinase and not ZAP70 for intracellular BCR 
signal transduction. However, CLL cells express both, Syk and ZAP70, and the 
presence of ZAP70 amplifies migration, proliferation and survival of CLL cells through 
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augmented BCR signalling (Chen et al., 2008; Feng & Wang, 2014). Hence ZAP70 is 
an attractive target for molecular therapy (Wang et al., 2010).  
Table 1.2: Summary of existing biomarkers for CLL and their clinical relevance: The key 
to risk stratification to standard therapies and/or overall survival. 
Biomarkers     
Low 
risk   
High 
risk   
        
Lymphocyte Doubling time  (LDT) >12 months < 12 months 
Chronmosomal aberrations      
13q14 del    favorable outcome   
Trisomy 12   intermediate risk   
11q23 del      poor survival 
17p13 Tp53     poor survival 
Complex Karoyotype     poor survival 
IgVH gene mutations       
Mutated( M)   longer survival    
Unmutated (UM)     short survival  
Zap70       poor survival 
CD38      short survival  
CD49d      short survival  
Serum markers       
TK1, β₂-miroglobulin and 
CD23    poor survival 
Novel gene mutatios       
Notch 1, SF3B1, Birc 3     poor survival 
MyD88    longer survival   
                
 
CD38 expression 
Damle et al, (1999) initially highlighted aggressive clinical behaviour of CD38 positive 
CLL cells indicating overall poor prognosis. CD38 is a surface receptor and acts as a 
cell surface enzyme (ectoenzyme) expressed on mature B-Lymphocytes and plasma 
cells (Thompson & Tam, 2014). The functional properties of CD38 are linked with the 
suppression of B cell lymphopoiesis in the bone marrow and induction of activation, 
proliferation and cytokine secretions in germinal B cells (Burger et al., 2009; He C et 
al., 2017). Like Zap-70, CD38 is also linked with BCR signalling: CD38+ CLL cells, in 
vitro, were more responsive towards BCR signaling than CD38- cells that are generally 
anergic (Morabito et al., 2010 and Benkisser-Petersen, 2015). Initial studies have 
placed CD38 expression in CLL cells as a useful and reliable prognostic marker 
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(Bürgler, 2016) based on CD38 expression versus IGVH mutation status. However, 
other studies revealed variability in the expression of CD38 which appears to be 
unstable on CLL cells throughout the clinical course of the disease (Nabhan, 2015). 
Moreover, expression of CD38 cannot be correlated with IGVH status and hence is 
considered as an individual prognostic marker, where high expression CD 38 is related 
to increased proliferation of CLL cells and low survival rate of CLL patients (Cramer 
and Hallek, 2011). 
CD49d 
CD49d, also known as very late antigen-4 (VLA-4), is a recently established prognostic 
marker. It is an α4 adhesion molecule expressed on B and T cells and on CD34+ 
hematopoetic stem/progenitor cells (Damle, 1999; Bulian, 2014; Baumann, 2016). 
Zachettto et al, (2012) confirmed the association between CD49d and CD38 expression 
by demonstrating that combined high expression of CD38high/CD49dhigh leads to the 
poor overall survival and shorter time to first treatment (Zachetto et al., 2012). In 2008 
two studies established CD49d as a negative prognostic marker and later studies 
confirmed it (Gattei et al., 2008; Shanafelt et al., 2008; Giudice 2016). Moreover, 
Brachtl et al., (2014) maintains that presence of CD38 and CD49d in CLL cells not only 
signifies an aggressive course of disease but these molecules also play an important 
role in pathogenesis of CLL. Therefore, these two molecules should be exploited further 
for developing new novel approaches in combination with currently developed targeted 
therapies (Brachtl et al., 2014). 
Serum markers 
There are several serological biomarkers such as serum thymidine kinase (TK1), β2-
microglobulin and soluble CD23, which also contribute to the prognosis of CLL at early 
stages (Hallek et al., 1999; Parker, 2011). Serum TK1 is a cellular enzyme and has a 
key role in DNA synthesis. Its level is high in dividing neoplastic CLL cells and its 
expression correlates with tumour mass, therefore can predict disease progression at 
an early stage (Konoplev et al., 2010). A high concentration of serum β2-microglobulin 
correlates with a high tumour burden and shorter progression free survival time, and 
hence it is associated with poor prognosis (Sevov et al., 2012). Serum CD23, a low 
affinity receptor for IgE is reported to represent an adverse prognostic indicator at the 
early stages of the disease course. Studies have shown that high levels of CD23 in 
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CLL cells can lead to diffuse bone marrow infiltration with CLL cells (unfavourable 
structural feature), decreased lymphocyte doubling time (LDT) and shorter overall 
survival (Wierda et al., 2005; Nabhan and Rosen, 2014). 
Novel gene mutations 
Out of the numerous recurrent gene mutations characteristic for CLL, the four most 
common gene mutations that are extensively researched for better understanding of 
underlying pathogenesis of CLL are Notch 1, SF3B1, BIRC3 and MYD88. All of these 
have demonstrated a direct functional and clinical association with prognostic 
parameters of CLL, and only MYD88 mutations identified in younger CLL patients has 
demonstrated favourable outcome (Puente et al., 2011 and Swerdlow et al., 2016). 
Notch1 
Notch1 mutations are identified in approximately 12% of CLL cases resulting in the 
decrease in overall survival of CLL patients (Fabbri et al., 2011, 2017). Ninety percent 
of the activating mutations are detected at the threonine (PEST) domain that generates 
constitutively active Notch 1 protein with a deficient C-terminal. Notch1 mutations result 
in the formation of a variant of plasma cell that support nuclear factor kB (NF-kB) 
signaling pathway resulting in increased cell survival and resistance to apoptosis in CLL 
cells (Rossi et al., 2012, 2016). Notch 1 mutations are reported to be more frequent in 
patients harbouring trisomy 12 karyotype and unmutated IGVH genes. CLL patients 
with Notch 1 mutations usually demonstrate a progressive refractory disease with 
increased risk of Richter syndrome transformation (transformation of CLL to the 
agressive diffuse large B cell   lymphoma) (Rosati et al., 2018). 
SF3B1 
Splicing factor, 3b, subunit 1(SF3B1) encodes a protein component that is needed by 
mRNA prior to protein synthesis. Recurrent mutations result in abnormal splicing. 5-
15% of patients displayed SP3B1 mutations along with the ATM mutations and 11q 
deletion suggesting an aggressive course of the disease (Wang et al., 2011; Quesada 






Mutations in BIRC3 results in malfunctioning of MAP3K14 kinase causing an increase 
in NF-kB pathway signaling leading to the increase in survival of CLL cells and shorter 
progression free treatment time (Rossi et al., 2013). BIRC3 mutations are seen at low 
frequency in newly diagnosed patients (4%) but at a higher frequency (25%) in relapsed 
refractory patients (Nadeu et al., 2016). Patients with BIRC3 mutations have a poor 
prognosis with overall survival of 3.5 years (Alhourani et al., 2016). 
MYD88 
Myeloid differentiation primary response 88 (MYD88) mutations have been found in 
only 5% of CLL patients. They occur in Toll like receptors (TLR) signalling pathways 
coding regions and are most frequent in young patients (Baliakas et al., 2015). Patients 
with MYD88 mutations often have low expression levels of CD38 and ZAP70 on CLL 
cells and belong to M-CLL category (Qin et al., 2017). Overall survival of patients with 
mutated TLR/MYD88 is better than without the mutation hence predicting a favourable 
outcome (Martinez et al., 2016). 
1.6 Treatment of CLL 
As mentioned earlier, CLL is a heterogeneous disease where patients follow different 
clinical course depending upon initial diagnosis, age, clinical and prognostic indicators. 
Depending on the stage at which the disease is diagnosed, a patient may be regularly 
monitored with a “wait and watch” option. CLL patients with an indolent course of the 
disease may remain asymptomatic for many years and starting treatment at this early 
stage will not benefit patients (Gribben, 2010). Treatment is only recommended when 
the course of the disease gets aggressive with unfavourable prognostic indicators. 
Currently there are various treatment options available such as chemotherapy with 
alkylating agents and purine analogues, immunotherapy, molecular therapy, or 
combination therapy. In more severe cases when CLL spreads to bone marrow or other 
organs, stem cell transplantation is considered the suitable approach. There is no cure 
of CLL yet, but modern treatment can lead to long-term remission, although minimal 





Depending upon fitness of a patient and physical condition at the start of treatment, 
oral chemotherapy with alkylating agents such as Chlorambucil and 
Cyclophosphamide had been a first choice of treatment for many years. Both alkylating 
agents were favoured due to low cost, low toxicity and easy oral route administration 
but demonstrated low complete remission (CR) and no benefits to overall survival of 
CLL patients (Eichorrst et al., 2009). Corticosteroids showed promising results initially, 
but later high incidence of infections was reported with its continued usage. Better 
responses were observed with combination therapy of chlorambucil and prednisone 
(CR 60% to 90%) than with Chlorambucil monotherapy, and this combination remains 
the first choice of treatment when patients are unfit to tolerate stronger available 
chemotherapy treatments (Rai et al., 2009). 
With the discovery of purine analogues Fludarabine monophosphate (Fludara), 2-
chlorodeoxyadenosine (2-CDA), physically fit CLL patients had better treatment options 
than alkylating agents with significant effect on their overall rate (60 - 80% with 
remission duration 3-5 years). Purine analogues are potent inhibitors of DNA and can 
induce p53-mediated apoptosis. Mutiple studies demonstrated that the overall 
response rate with Fludarabine monotherapy is significantly higher, 63 to 73%, with 
complete remission in 7-40% cases, compared to the alkylating CAP regimen 
(cyclophosphamide, doxorubicin, and prednisone) and Chlorambucil alone (Leporrier 
et al., 2001; Eichhorst et al., 2006; Catovsky et al., 2007). However, patients with 
unfavourable prognosis, relapse and need subsequent therapy such as 
immunotherapy (Robak et al., 2010). 
Immunotherapy 
Monoclonal antibodies act by employing body’s own natural immune responses such 
as antibody dependent cellular cytotoxicity (ADCC) by Natural Killer (NK) cells, 
activation of the classical complement pathway and/or apoptosis. Several monoclonal 
antibodies such as Rituximab and Ofatumumab (directed at CD 20) and Alemtuzumab 
(directed at CD52) are among the most common frontline therapy for treating CLL 
(Wierda et al., 2010; Pettitt et al., 2012). Obinutuzumab (GA101) is another novel CD20 
mAb that has demonstrated significantly increased ADCC compared with Rituximab. 
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New mAbs directed at anti-CD37, anti-CD19 and anti-CD40 have shown promising 
results in treating CLL in clinical trials (Frustaci et al., 2016). 
 
 
Figure 1.3 Current and Future monoclonal antibodies as frontline treatment of Chronic 
Lymphocytic leukemia. Monoclonal antibodies (mABs) act via several mechanisms to recruit 
immune responses, such as complement activation (CDC), activation of cytotoxic effector cells (ADCC) 
or phagocytosis (ADP) (Robak et al., 2016). 
 
Combined chemo- and immunotherapy 
The introduction of combination chemotherapy known as chemoimmunotherapy in CLL 
treatment has led to better response and progression free survival. The three main 
treatment regimen currently being used are FC (fludarabine, cyclophosphamide), FCR 
(Fludarabine, Cyclophosphamide and Rituximab) and FR (Fludarabine and Rituximab). 
For young and physically fit patients who have no renal problems and without the 17p 
deletion and P53 mutations, the first line of treatment is FC or FCR (Hallek et al., 2010). 
In relapsed older patients or those with more co-morbidities, FR or combination therapy 
with Bendamustine and Rituximab showed promising results with response rate 
approaching 90% (Fischer et al., 2011). Overall survival rate is higher and almost 
similar in both FC and FCR regiments, but response rate appears higher in case of 
FCR, whilst the level of toxicity (side effects) is significantly lower in FR regimen. 
Complete remission (CR) is seen in 47 to 70% patients when treated with FR or FCR 
regimen respectively (Eichhorst et al., 2014). Ofatumumab is another CD20 mAb that 
has been combined with FC and FCR to be used as front-line therapy and showed 
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improved outcome in CLL patients (Rai and Jain, 2016). Alemtuzumab (anti-CD52) 
when used in combination with FCR in patients with 17p deletions and TP53 mutations 
showed overall efficacy but with major toxicites therefore was removed from trial (Rai 
and Jain, 2016.) 
Molecular therapy 
In the last 4 years, there has been an upsurge in understanding the pathogenesis of 
CLL and as a result targeted molecular therapies have been developed. This 
particularly involves targeting BCR signal transduction pathway inhibitors such as 
inhibitors of Lyn, Syk, Bruton’s tyrosine kinase (Btki), phosphatidynilisotol 3 kinase 
(PI3Ki), and BCL2 (BCL2i), have dramatically improved treatment options for patients 
with high-risk CLL. (Figure 1.3). 
Of these the most significant todate are Ibrutinib, Idelalisib and (ABT-199) Venetoclax 
(Dreger et al., 2018). Pan et al., (2007) and Honigberg et al., (2010) have developed 
Iburutinib, an irreversible inhibitor of BTK. It was shown to be more effective than 
Ofatumumab in the patients with relapsed CLL by inducing higher response rates as 
well as longer progression free survival (PFS) and overall survival (OS) in the 
RESONATE trial (Byrd et al., 2013, 2014). A remarkable shrinkage in lymph nodes was 
observed accompanied by a shift of lymphocytes to peripheral blood. This drug also 
has a dual mechanism of action on signaling and inhibition of cross-talk in CLL 
microenvironment (Burger et al., 2015). Idelalisib is a selective and reversible inhibitor 
of phosphatidylinositide 3-kinase (PI3K) and promotes apoptosis of CLL cells. In 
patients with relapsed CLL, Idelalisib, in combination with Rituximab or Ofatumamab 
was shown to induce higher response rates and longer PFS and OS compared to 
Rituximab monotherapy (Brown et al., 2014; Furman et al., 2014). Both inhibitors, 
Ibrutinib and Idelalisib are well tolerated in long-term therapy and they could be used 
in elderly patients with coexistent conditions. Idealisib was further shown to have 
remarkable inhibitory effect on lymphocyte trafficking, chemokine networks and T cells 
in CLL microenvironment (O’Brien et al., 2015). Another recently approved orally 
bioavailable dual inhibitor of PI3K δ and PI3K γ isoforms is Duvelisib (IPI-145, INK 
1197). Duvelisib has shown clinical activity with relapsed or refractory R/R CLL patients 
with an overall improved median progression-free survival (PFS) by 3.5 months more 
than Ofatumamab (Lawrence, 2018). 
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Another successful drug is Venetoclax which is a higly selective antagonist of 
antiapoptotic protein BCL2. In clinical trials, Venetoclax showed no effects on platelets 
but induced apoptosis of CLL primary cells containing high expression of BCL2. The 
overall response rate was high (79%) with 20% demonstrating complete response and 
66% showed 15 months progression free survival rate (Roberts et al., 2016). 
Lenalidomide is another immunomodulatory drug that acts on the CLL 
microenvironment by inhibiting TNF, altering cytokine secretion and enhancing T-cell 
immunological synapse formation with CLL B cells (Kater et al., 2014; Byrd et al., 2018). 
Lenalidomide has shown efficacy in relapsed refractory setting in clinical trials:  ORR 
was 65% and CR was 10% (Facteu et al., 2014; Itchaki and Brown, 2017). 
CART-T Cell Therapy 
One of the relatively recent advances in CLL therapy is chimeric T cell receptor (TCR) 
specific for CD19 (CART-19) (Porter et al., 2015; Kalos et al., 2016). Autologous T cells 
from CLL patients were collected and reintroduced into patients’ blood following genetic 
engineering with the expression of an anti-CD19 chimeric TCR, which is produced by 
combining an antigen recognition domain of a specific antibody (CD19) with an 
intracellular domain of the CD3- zeta chain or FcγRIin T cells. After a 4-year follow up 
of 14 RR-CLL patients, the ORR was 57% and four patients achieved CR. None of the 
patients in CR have relapsed (Porter et al., 2015, 2016). Recent studies show that 
CAR-T cell therapy is highly effective in relapsed or refractory CLL patients who failed 
treatment with Ibrutinib (Turtle et al., 2017). 
Despite of these advances in the treatment of CLL, the disease remains incurable. One 
of the limiting factors is heterogeneity of CLL which means a single therapy is not 
suitable for all the patients. Therfore there is a need for the development of novel 
therapeutics approaches that enable patients to receive personalised treatments to 
achieve a better response. 
1.7 B cell receptor signalling in CLL 
The role of BCR-mediated signalling in prognostication and stratification of CLL 
associated with survival and expansion of CLL cells has been under extensive 
investigation during the last decade. The complexity of BCR signalling permits many 
distinct outcomes, including survival, tolerance (anergy) or apoptosis, proliferation, and 
differentiation into antibody-producing cells or memory B cells. BCR activation can 
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happen in two distinct ways: antigen induced or antigen independent autonomous BCR 
signaling termed “Tonic signalling” (Figure 1.3). Antigen dependent signaling involves 
cross-linking of BCR with a specific antigen, ITAMs phosphorylation and consequently 
activation of a signaling cascade leading to the cell survival and proliferation. In 
contrast, Tonic signaling involves BCR activation possibly without cross-linking, via 
auto-antigensor microbial antigens present in the tissue microenvironment (Packam et 





Figure 1.4 Antigen dependent (a) and Antigen independent (Tonic, b) BCR signaling in 
CLL. CLL cells follow two forms of receptor signaling leading to survival and proliferation. Antigen 
independent “Tonic signaling” generates within the tissue microenvironment due to the mutations of BCR 
signaling pathway while antigen dependent signaling results from BCR ligation by specific antigens 







Below I present some of the key components of the BCR-mediated signalling in more 
details. 
 
Surface Immunoglobulin sIgM and sIgD 
All mature B cells co-express IgM and IgD receptor isotypes (Figure 1.5).  
 
Figure 1.5 B cell receptor (BCR). The BCR complex consists of various components: Ig membrane 
attached surface IgM/IgD receptors and associated accessory molecules CD79A and CD79B. The B cell 
receptor extends both outside the plasma membrane (extracellular) and inside the cell (Intracellular) 
(Barnea et al., 2014). 
 
BCR signaling via IgM and IgD is now recognised as the central pathogenic pathway 
in CLL (Burger and Chiorazzi, 2013). IgM and IgD receptors along with coreceptors 
CD19 and CD20 help B cell transition from resting state to activated state and thus 
maintaining the signaling balance and regulation of B cell fate (Mazarello et al., 2017). 
Due to their structural similarity it was originally thought that their functional responses 
were similar too following antigenic stimulation. However, studies on knockout mouse 
models have revealed that their function is interchangeable and IgD can easily 
substitute for IgM functions in case of low-density expression of IgM or loss of the IgM 
receptor (Simonetti et al., 2014). CLL cells are characterised by a variable expression 
of IgM and IgD receptors, and multiple studies on BCR signaling have demonstrated 
the importance of IgM signaling pathway in CLL cells for survival, cell cycle entry and 
proliferation. However, studies on the IgD-mediated CLL responses have led to 
contradicting conclusions, such as cell survival or apoptosis (Stevenson et al., 2014).  
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Difference in the outcomes following IgM and IgD stimulation is also observed in regard 
to the IGVH mutations. IgM, but not IgD-mediated responses are typically augmented 
in U-CLL cases (Mockridge et al., 2007).  
It has been demonstrated that IgD receptors, following stimulation were rapidly 
internalized and fail to activate downstream responses (Burger et al., 2009). 
Haerzschel et al, found that following stimulation there is an amplification of IgD 
expression and IgD mediated calcium signaling, significantly different from IgM 
expression and the chemotaxis towards CXCL12 and CCL21 is significantly reduced in 
IgD but not in IgM (Haerzscel et al., 2016). Although IgM and IgD are similar in 
structure, differences in their responses probably contribute to the variable clinical 
behaviour of CLL. Therefore, understanding the details of the BCR signal transduction 
through the combination of BCR components offers an opportunity for the precise 
targeting by the PK inhibitory drugs (Apollonio et al., 2013).   
CD79a/79b 
CD79a (Ig-α) and CD79b (Ig-β) are transmembrane signaling molecules of BCR that 
form a heterodimer complex on B cells known as BCR complex and have molecular 
weights of 20 kDa each. Human CD79a is coded by gene mb-1 which is located on 
chromosome 19 and the gene coding for CD79b is B29 located on chromosome 17 
(Sims, 2012).  CD79a/b play a critical role in B cell maturation, survival and activation. 
CD79a is expressed at early stages of B cell development persisting from pre-B stage 
to the last stage of maturation before differentiation into plasma cells (Patterson, 2011). 
The cytoplasmic tails of the dimer CD79a/b contain Immunoreceptor tyrosine–based 
activation motifs (ITAMs). Antigen binding to the BCR results in phosphorylation of 
CD79a and CD79b via ITAMs leading to the recruitment and activation of the kinase 
Syk. Syk activation then initiates further signal transduction leading to cytoskeletal 
reorganisation and changes in gene expression for B cell maturation (Hecken and 
Burger, 2016). 
CD79a and CD79b are heterogeneously expressed on CLL cells. Vuillier et al (2005) 
have reported that glycosylation and folding defects are responsible for the low 
expression of the CD79a chains in CLL patients. Among other defects that have been 
recorded are reduced expression of CD79b mRNA (Thompson et al., 1997), somatic 
mutations of the B29 gene (Thompson et al., 1997), over-expression of a product of 
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alternative splicing of CD79b, termed as alternative transcript of CD79b  (ΔCD79b) 
(Alfarano et al., 1999), and abnormal assembly of BCR chains, leading to CD79b 
accumulation in  intracellular compartments (Payelle-Brogard et al., 2002). 
P13K/AKT pathway 
AKT (Protein Kinase B) is a serine/threonine-specific protein kinase that is essential for 
the proper functioning of cellular processes such as  glucose 
metabolism, apoptosis, cell survival and proliferation, transcription and cell cycle 
progression (Manning and Toker, 2017). AKT is the founding member of PKB family 
composed of three members AKT1, AKT 2, AKT 3. Activation of these kinases in cells 
takes place in response to diverse stimuli such as hormones, growth factors, and 
extracellular matrix components and promotes survival and growth (Fruman et al., 
2017). AKT remains in the cytosol in an inactive state, until the cell is stimulated and 
translocates to the plasma membrane with the help of PI3K. PI3K activates 
phosphatidylinositol 3, 4, 5, -triphosphate (PIP3) which recruits phosphatidylinositol-
dependent kinase 1 (PDK1). PDK1 partially phosphorylates AKT1 at threonine 308, but 
full activation of AKT requires additional phosphorylation at serine 473 by other kinases 
including phosphoinositide-dependent kinase 2 (PDK2), integrin-linked 
kinase (ILK), mechanistic target of rapamycin complex (mTORC) and DNA-dependent 
protein kinase (Limon and Fruman, 2014; Manning and Toker , 2017). The cellular 
levels of PI3K products are controlled by the balance between PI3K activity and the 
phosphatase activity of PTEN (phosphatase and tensin homolog mapped on 
chromosome ten). Interestingly, PTEN protein is reduced or not detected in 48% of 
patients with CLL (Backer et al, 2010, 2016). AKT is dephosphorylated by protein 
phosphatase 2A (PP2A) and the PH-domain leucine-rich-repeat-containing protein 
phosphatases (PHLPP1/2). In addition, the tumor suppressor phosphatase and tensin 
homolog (PTEN) inhibits AKT activity by dephosphorylating PIP3 (Baracho et al., 
2011). It has been shown that in CLL cells PI3K pathway is constitutively activated 
leading to AKT activation with subsequent phosphorylation of other downstream 
signaling molecules (Figure 1.6). Dysregulation of the PI3K/AKT pathway is implicated 
in a number of human diseases including cancer, diabetes, cardiovascular disease and 





Figure 1.6. AKT/P13K signal transduction pathway. The P13K is required to activate 
AKT/mTOR pathway and together they regulate various aspects of cellular development such as cell 




AKT regulates cell growth through its effects on the TSC1/TSC2 complex and mTORC 
signalling and contributes to cell proliferation via phosphorylation of the CDK inhibitors 
p21 and p27. AKT is a major mediator of cell survival through direct inhibition of pro-
apoptotic proteins like Bad or inhibition of pro-apoptotic signals generated by 
transcription factors like FoxO. AKT also regulates NF-κB signalling by phosphorylating 
IKKα and Tpl2 (Bozulic and Hemmings, 2009; Hers et al., 2011).  It is critically involved 
in the regulation of metabolism through activation of AS160 and PFKFB2. In addition, 
AKT has been shown to regulate proteins involved in neuronal function including the 
GABA receptor, ataxin-1 and huntingtin proteins. AKT contributes to cell migration and 
invasion via phosphorylation of palladin and vimentin. Barragan et al, (2006) 
demonstrated that activation of the AKT pathway is possible by another PI3K-
independent pathway that takes place via protein kinase Cβ (PKCβ) suggesting the 
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presence of two different pathways used by CLL cells for AKT Phosphorylation.  Due 
to the critical role of AKT/PKB in regulating diverse cellular functions it is an important 
therapeutic target for the treatment of human disease. 
AKT inhibitors block the anti-apoptotic proteins Mcl-1 which causes an increase in the 
expression of tumour suppression gene 53 leading to induction of extensive apoptosis 
of malignant cells (Furman et al., 2010; Fruman et al., 2017). Targeting AKT has been 
a pharmacological challenge and several promising AKT inhibitors have been 
developed that either selectively or nonselectively inhibit the three isoforms of AKT by 
binding to the kinase or PH domains. Two of the most competitive inhibitors A-443654 
and AKti1/2 are reported to inhibit AKT phosphorylation by blocking cell survival and 
cell cycle progression. A-443654 is a pan AKT-inhibitor which can act against all three 
isoforms AKT1, AKT2 and AKT3 in equal potency. In contrast AKti1/2 is a highly 
selective inhibitor which effects only AKT1 and AKT2 but not AKT3 activity (Luo et al., 
2005; Bain et al., 2007). Another known selective inhibitor of isoform PI3Kδ is Idealisib 
(formerly knows as CAL-101) that induces apoptosis in CLL cells by inhibiting 
prosurvival signalling pathways. It also blocks the supportive effect of many micro 
environmental factors, mainly NLCs activation of the BCR, and of CD40L, BAFF, TNF-
α, or fibronectin and promotes CLL cell migration out of lymph node into the blood 
(Herman et al., 2010, 2014; Ali et al., 2014).  Idealisib combined with the anti-CD20 
antibody Rituximab significantly improved progression free survival (81%) and overall 
survival (91%) in relapsed CLL patients (Fruman et al., 2014, 2017). Furthermore, a 
recent publication showed that combination of Idealisib with Ibrutinib is potentially 
benficial for CLL patients (Rooji et al., 2015). Duvelisib (IPI-145) is another potent, dual 
inhibitor that targets both PI3Kδ and PI3Kγ isoforms (Winkler et al, 2013). Clinical 
evaluation of Duvelisib demonstrated that it inhibits BCR mediated signalling and 
chemotaxis in response to CXCL12 and induces apoptosis in CLL samples 
(Balakrishnann et al., 2015). Most importantly it has been seen that Duvelisib can 
overcome Ibrutinib resistance and is potentially beneficial for treating patient’s 
refractory to Ibrutinib (Dong et al., 2014). TGR-1202, copanlisib, GS-9820 and MK2206 
are the next-generation PI3Kδ inhibitors that have demonstrated activity in patients with 




 MAPK/ERK Kinase 
The Mitogen activated protein kinase/extra cellular regulated kinase (MAPK/ERK) 
pathway is another signalling pathway induced by BCR stimulation. This complex 
pathway plays a key role in many cellular functions including cell proliferation, gene 
expression, differentiation, cell survival and most importantly inducing apoptosis 
(Pearson et al., 2001 and Siegfried et al., 2013). 
MAPK are serine-threonine protein kinases and so far, 3 classes of mammalian MAP 
kinases have been identified: the extracellular signal-regulated protein kinases (ERK-
1/2), the c-Jun N-terminal kinases (JNK1/2/3) and the p38 stress-activated protein 
kinases (p38MAPKα, β, δ and γ). ERK, JNK and p38 isoforms are grouped according 
to their activation motifs and function. ERK predominantly regulates anti-apoptotic and 
mitogenic gene expression in response to cytokines and growth factors. The other 
kinases p38 and JNK activation depend on cellular and environmental stress including 
proinflammatory stimuli and growth factors and mainly control apoptosis and cell cycle 
progression (De Luca, 2011; McCain, 2013). 
Following BCR stimulation, the G proteins recruit retrovirus-associated DNA sequences 
(Ras) and rapidly accelerated fibrosarcoma (Raf) proteins.  Activated Raf 
phosphorylates and activates mitogen activated ERK protein kinase (MEK). MEKs 1 
and 2 phosphorylate ERK, MEKs 3, 4, and 6 phosphorylate p38, whilst MEKs 4 and 7 
activate JNK pathways. The transcription factors regulated by MAPK include Elk-1 and 
cmyc by ERK, c-Jun and ATF-2 by JNK, and ATF-2 and MAX by p38 MAPK (Figure 
1.7), and the functional outcome of activation is dependent on the developmental stage 
of the B cell (Rodriguez and Crespo, 2011; McCain, 2013). 
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Figure 1.7. Schematic overview of MAPK kinase signalling pathway. The three major factors 
such as cytokines, cellular stress or inflammatory agents lead to the activation of three major MAPK 
pathway leading to ERK, p38 or JNK pathway via RAS and RAF signaling and consequently induce its 
biologic effects on target cells (modified from Hemmaker and Firestein, 2010) 
The p38MAPK is known to be associated with proliferation and survival in general but 
multiple studies have demonstrated its role in inducing apoptosis by cellular stress in 
CLL. Both, survival and apoptosis response can be mediated by transcriptional and 
posttranscriptional mechanisms, which directly affect death receptors survival pathway 
or pro- and anti-apoptotic Bcl-2 family proteins (Shukla et al., 2018).  It has been 
demonstrated that isoform p38α can negatively regulate cell cycle progression at both 
the G1/S and G2/M transitions by a number of mechanisms, including downregulation 
of cyclins and upregulation of CDK inhibitors (Lake et al., 2016). Additionally, Muzio et 
al, (2008) suggested that MAPK pathway can become a potential target for 
pharmacological intervention with therapies as selected cohort of their CLL patients 
exhibited constitutively phosphorylated MAPK ERK, in vivo, following BCR triggering 
but not, in vitro. Their results indicated that constitutive activation pattern of the MAPK 
kinase pathway in a subset of CLL patients together with increased activity of nuclear 
factor of activated T cells (NF-AT) in an absence of AKT phosphorylation and 
unresponsiveness of BCR, may be regarded as molecular characteristics of anergy in 
human B cells (Muzio et al., 2008; Woyach and Johnson, 2015). The known inhibitors 
Ibrutinib (BTK), Idealisib (P13K) and Fostamatinib (Syk) have shown to suppress the 
activity of MAPK kinase signaling in human and murine cells by blocking the activity of 
chemokine CXCR4 in the proliferation centres (Chen et al., 2016). Two MAPK inhibitors 
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Vemurafinib and Trametinib target BRAF and MEK1/2 to inhibit MAPK signaling by 
blocking the proliferation, migration and survival of CLL cells (Crassini et al., 2015; 
Shukla et al., 2018). 
Bruton tyrosine kinase (BTK)  
Bruton tyrosine kinase (BTK), a non-receptor cytoplasmic kinase is a critical member 
of Tec family of kinases due to its key role in B cell development, differentiation, 
signaling, proliferation and survival. B cells express BTK from early precursor to mature 
B cells, it is also expressed by myeloid cells but not by plasma cells or T lymphocytes 
(Satterthwaite, 2000, 2018). Any genetic mutation, loss of function or absence of BTK 
results in defective B cell development by blocking B cell maturation between the pro 
and pre-B cell stages causing severe decline in circulating mature B lymphocytes 
(Buggy, 2012). Genetic deletion of BTK is seen to cause in humans X-linked 
agammaglobulinemia (Bruton agammaglobulinemia, XLA), which is characterized by 
virtually the complete absence of B cells and non-production of immunoglobulins to 
generate humoral responses leading to recurrent bacterial infections (Vetrie et al., 
1993). In mice loss of BTK genes causes less severe X-linked immunodeficiency (Xid) 
(Rawlings et al., 1993). 
BTK has 3 functional domains, pleckstrin homology (PH) domain and Src homology 
SH3 and SH2 domains and each of these domains can potentially interact with proteins 
critical for activation and regulation of intracellular signaling (Mohammed et al., 2009 
and Gusstafson et al., 2017). Following antigenic stimulation of BCR and signal 
transduction via CD79a and CD79b, BTK translocates to the plasma membrane binding 
to phosphatidylinositol -3,4,5-triphosphate (3-5) at its PH domain, where it gets partially 
phosphorylated at Y551 by a Src family kinase (SFK), presumably Lyn. Full activation 
involves autophosphorylation by Src family kinases at Tyr223 within the SH3 domain. 
B-cell linker protein (BLNK) at SH2 domain acting along with SH3 domain 
phosphorylates phospholipase C, gamma 2 (PLCγ2), which leads to production of the 
second messenger diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP3) which 
results in triggering the downstream signaling. In CLL this triggering causes enhanced 
activation of P13 kinase, PLCγ2 and NF-κB signaling leading to survival and 
proliferation of malignant cells. BTK is dephosphorylated at SER180 by negative 
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regulated PKCβ, blocking its membrane recruitment and subsequent activation 
(Hendriks et al., 2014; Smith, 2016). 
The role of BTK in the amplification of BCR signaling leading to constitutively active 
pathway of CLL survival has been very well characterized in recent years. Targeting 
BTK became a promising strategy and to date Ibrutinib is the most successful orally 
bioavailable irreversible inhibitor of BTK that has shown excellent results clinically with 
extended durable remissions in both untreated and relapsed patients (Woyach et al., 
2014). Studies have shown that Ibrutinib can interrupt BTK auto phosphorylation 
following IgM ligation that results in decrease in the expression of intracellular signaling 
targets via ERK, NF-κB and AKT leading to survival and proliferation (Herman et al., 
2014). In addition, it has been demonstrated that Ibrutinib not only inhibits the 
proliferation of malignant B lymphocytes in vivo but can also inhibit microenvironmental 
survival proliferation and migration signals by blocking the effect of stromal coculture, 
in vitro, (Burger et al., 2009; Herman et al., 2011; Gayko et al., 2015). 
Ibrutinib/PCL-32765 covalently binds to BTK protein through its cysteine residue 481 
and inhibits its phosphorylation at TYR223 ATP binding domain of BTK for 24 hours. 
Although Ibrutinib induces lymphocytosis in CLL patients during their first week of 
treatment it is resolved within one-month therapy.  Therefore, treatment delays or 
discontinuation of therapy due to side effects of therapy is infrequent (Woyach et al., 
2012, 2014). The second-generation BTK inhibitor, Acalabrutinib and two other 
potential BTK inhibitors CC-292 and ONO-4059 have demonstrated therapeutic 
efficacy based on their anti-proliferative activity (Burger, 2014; Byrd et al., 2016). 
1.8 The role of microenvironment in CLL cell survival 
It is widely accepted that CLL cell behaviour is not only regulated by the engagement 
of BCR by (auto) antigens but CLL cells rely on other stimuli from microenvironment to 
survive and to proliferate. It has been documented that despite expressing high levels 
of Bcl-2, CLL cells undergo rapid and spontaneous apoptosis when cultured under, in 
vitro, conditions unless they are cocultured with accessory stromal cells. This 
demonstrates that prolonged, in vivo, lifespan of CLL cells is at least partially due to 
microenvironmental influences and BCR engagement by antigens (Ghia et al., 2008; 
Burger et al., 2009; Oppezzo and Dighiero, 2013). CLL cells within proliferating centres 
or “pseudofollicles” modify microenvironment to create optimum surroundings to 
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facilitate leukemic cell survival, proliferation, homing and tissue retention. Direct contact 
between CLL cells and accessory cells such as T and NK cells, Nurse like cells (NLCs) 
and stromal cells supported by secreted cytokines IL-4, TNFα, INFγ and CLCX12 aid 
in rescuing CLL cells from apoptosis promoting their survival and expansion (Burger, 
2011). Messmer et al, (2005) suggested that in the proliferating centres the daily 
cellular birth rate accounts for approximately 1 to 2% of the entire CLL clone.  
Stromal cells are considered critical element of tissue environment of CLL as they may 
serve to protect CLL cells from spontaneous and drug induced apoptosis. They 
constitutively secrete chemokine CCL19 and CCL21 which provide an important 
chemokine gradient for the trafficking and homing of CLL cells from periphery to 
lymphoid organs (Hacken and Burger, 2014, 2016).  NLC secrete CXCL12 (also known 
as stromal cell-derived-growth-factor 1) and CXCL13 which binds to the receptors 
CXCR4 and CXCR5 expressed on CLL cells and attracts CLL cells towards the tissue 
microenvironment. NLCs can also support survival of CLL cells by expressing B cell 
activating factor (BAFF), and proliferation inducing ligand APRIL which in turn 
stimulates B cell maturation transmembrane activator (BCMA). Further prosurvival 
signals are provided by interaction of CD31 expressed on NLCs and CD38 on CLL cells 
contributing to the failed apoptosis and increased production of CLL cells (Burger, 
2013). In addition, in CLL the de-regulated functional capability of T cells and NK cells 
assists CLL cells to escape immune mediated cytotoxicity (Ramsay et al., 2012; 
Rainers et al., 2013; Riches et al., 2013). 
Taken together (Figure 1.8), the crosstalk between CLL cells and tissue 
microenvironment deliver signal that favours clonal expansion and drug resistance and 




Figure 1.8 CLL cells and lymphoid tissue microenvironment. CLL cells are dependent on pro-
survival signals generated from microenvironment elements such as NLCs, MSCs, chemokines, 
interleukins CD49d and T cells. NLCs and MSCs secrete CXCL12 and CXCL13 and attract CLL cells 
through CXCR4/CXCR5 receptors. The receptor VLA-4 (CD49d) interacts with MSCs via VCAM1 and 
Fibronectin and facilitates cell – cell adhesion. The receptor CD31 for CD38 on NLCs induces Zap-70 
phosphorylation thus activating BCR mediated signaling pathways. Furthermore, proliferation and 
survival of CLL cells can be triggered by CD40L and IL4/21 provided by T cells and by the BAFF and 
APRIL derived from NLCs (Spaargaren et al., 2015)  
 
 
1.9 Dysregulation of Apoptosis in CLL 
 Although initially CLL was considered a static disease with uncontrolled accumulation 
of lymphocytes due to failed apoptosis, the current understanding is that proliferation 
occurs in secondary lymphoid organs in areas known as proliferation centres of tissue 
microenvironment leading to expansion and prolong survival of CLL cells in vivo 
(Chiorazzi, 2007; Reed, 2008; Wu et al., 2018) 
The major cause of inefficacy of most targeted therapies is acquired resistance towards 
apoptotic mechanisms, as evading apoptosis is one of the hallmarks of CLL cells. 
Owing to the fact that apoptosis causes minimum inflammation and damage to the 
tissue, targeting apoptotic pathways has been a centre of attraction for the development 
of new improved anti-cancer drugs. 
Apoptosis is a cell suicide mechanism that leads to characteristic morphological 
alterations such as membrane blebbing, reduced cytoplasm, chromatin condensation 
and fragmentation of genomic DNA eventually causing breakdown of a cell (Parrish et 
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al., 2013; Kalkavan and Green, 2017). It is an irreversible process regulated by a family 
of cysteine dependent aspartate specific proteases known as caspases. The caspases 
are divided into initiator caspases and executor caspases. The initiator caspases (8-9-
2-10) are responsible for interaction with adaptor proteins in response to apoptotic 
stimuli. Once activated initiator caspases then cleave effector caspases (3-7-6) thus 
triggering the activation of caspase cascade. Following initiation, effector caspases 
cleave a wide range of substrates including poly-ADP-ribose protein (PARP) that 
results in structural breakdown of cells and finally in apoptosis (Strasser, 2011; Koff et 
al., 2015).  
Apoptosis can be induced by two known pathways (Figure 1.9), either by intrinsic 
pathway following intracellular activation involving mitochondria (mitochondrial 
pathway) or by activation of cell surface receptors known as “death receptors”, the 
extrinsic pathway (Billard, 2014). Activation of the intrinsic pathway is triggered by a 
wide range of intracellular signals such as radiation, cytotoxic drugs, cellular stress and 
growth factor withdrawals, and is closely regulated by the Bcl-2 family proteins. Upon 
stimulation of apoptosis, the balance between pro-apoptotic proteins (Bax, Bak, Bcl-xS 
and Bcl-GL) and anti-apoptotic proteins or prosurvival proteins (Bcl-2, Bcl-XL, BCl-W, 
Mcl-1 and Af/BF1-1) is disturbed resulting in the release of Bax and Bak sequestered 
by prosurvival member of Bvel-2 family. The anti-apoptotic proteins contain BH1-4 
domain and a transmembrane domain, and the proapoptotic proteins have two multi 
protein domains (Bax, Bak, Bcl-xs and Bcl-GL) and only one BH3 (Bim/Bod, Bad, Bid, 
Bmf, Bcl-Gs, Blk, Hrk/DP5, Noxa and PUMA/Bbc3). On receiving apoptotic signals BH3 
domain proteins bind with prosurvival proteins and antagonise them to release 
activated Bax and Bak which increases permeabilisation of mitochondrial membrane. 
This allows the release of cytochrome C which forms an apoptosome containing 
adaptor protein Apaf-1, inactive initiator procaspase 9 and cytochrome C. Procaspase 
9 becomes activated in the apoptosome complex and cleaves caspases -8 and -9 thus 
triggering the activation of effector caspases. Once the effector caspase cascade is 
activated, the cell undergoes morphological and biochemical changes regulated by 
effector caspase 3 and becomes committed to apoptosis (Strasser, 2011; Billard, 2014; 
Czabotar et al., 2014). 
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Figure 1.9. Schematic overview of extrinsic (Mitochondria independent) and intrinsic 
(Mitochondria dependent) apoptosis pathways. The extrinsic pathway activation involves the 
binding of ligands to the death receptor that results in the formation of death inducing signaling complex 
(DISC). DISC enables activation of caspace-8, which then cleaves and activates executer caspases 3 
and 7 which then lead to demise of the cell. The intrinsic pathway is initiated following cellular stress 
causing activation of BH3 that leads to the recruitment of pro-apoptotic proteins Bax and Bak, and the 
release of cyctochrome C into the cytosol which forms an apoptosome with procaspase-9 and apoptotic 
protease activating factor-1 (Apaf-1). Activated caspase- 9 then cleaves caspase-3 and 7 allowing 
apoptosis process to continue to the cell death (Yuan et al., 2012). 
 
The extrinsic pathway also known as mitochondria independent pathway involves the 
ligation of death receptors which are members of the tumour necrosis factor receptor 
family such as (TNF-R, FAS, DR4) to their respecting ligands (TNF-L, FAS-L, TRAIL) 
thus exposing a death domain (DD) on the cytoplasmic site of the receptor. The binding 
of death receptor to its ligand recruits an adaptor protein and forms a death inducing 
signal complex (DISC). Within this DISC initiator caspase 8 and effector caspase 3 are 
cleaved and activated which leads to the demise of the cell.  
Apoptosis resistance in CLL is influenced by many factors. CLL cells demonstrate 
overexpression of Bcl-2 family proteins and the increased Bcl-2 /Bax ratio that induces 
cell survival instead of apoptosis has led to a significantly poor prognosis in CLL 
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patients (Packham et al., 2005, 2014). Another anti-apoptotic Bcl-2 family protein Mcl-
1 has been observed to promote cell survival in CLL as high expressions of MCL-1 
correlated with increased resistance to apoptosis and inability to attain complete 
remission following cytotoxic therapy (Pepper et al., 2008; Palma et al., 2015).  
Another factor that can cause dysregulation of apoptosis is alterations or loss of 
function of the P53 gene. Tp53 protein is a transcription factor also known as tumour 
suppressor protein 53 (TP53). It regulates cellular responses to DNA damages by 
induction of apoptosis, DNA recombination and cellular senescence. The ataxia 
telangiectasia-mutated gene (ATM) is the activated gene in the P53 signaling pathway 
which can block cell cycle progression and stimulate DNA repair. Any defects in 
P53/ATM gene can contribute to a reduced response to apoptosis signals and defective 
DNA repair mechanism and as a result an increased survival of CLL cells. A variety of 
factors can damage P53 gene such as radiation, various chemicals, and viruses such 
as the Human papillomavirus (HPV) and therefore over 50% of all human cancers have 
been detected with the mutation of P53/ATM genes in cytogenetic analysis (Zenz et 
al., 2010). In addition to above mentioned factors, changes in the expression of other 
apoptotic regulators such as the nuclear factor-kappa B (NF-κB) transcription factor and 
phosphatidylinositol-3 kinase (P1-3K) signalling pathways can induce cell 
survival. Many cytokines, including B-cell activation factor (BAFF), a proliferation 
inducing ligand (APRIL), CD40 ligand and interleukin-4 (IL-4) are activated in CLL cells 
and promote the survival of CLL cells, and CLL cells appear to be resistant to apoptosis 
if abnormalities are identified in signalling via cell-surface death receptors. Intracellular 
signaling following antigenic stimulation via BCR is also been recognised to influence 
apoptotic pathways in CLL due to presence of overexpression of apoptotic kinases in 







Factors affecting various apoptosis mechanisms are schematically summarised in 
Figure 1.10. 
 
Figure 1.10. Factors involved in the apoptosis resistance. The mechanisms by which the 
evasion of apoptosis occurs in cancer, including defective genes, reduced caspase function, damaged 
signaling pathways and overexpression of Bcl-2 proteins (Wong, 2011). 
 
Since dysregulation of apoptosis is a critical factor in the pathogenesis of CLL, 
strategies that induce apoptosis of malignant cells and bypass Bcl-2 will be 
therapeutically useful. This would require an improved understanding of a correlation 
between defective apoptosis in CLL and responses to therapy. 
1.10 B cell anergy in CLL 
Several studies have demonstrated the presence of anergic cells in CLL (Apollonio et 
al, 2013; Caligaris-Cappio, 2014; Packham et al, 2014). Anergy is one of the strategies 
adapted by immune system to silence autoreactive B lymphocytes on continuous low–
affinity recognition of self-antigens (Ag) resulting in cell unresponsiveness when these 
B lymphocytes were further stimulated through BCR. CLL cells were always been 
characterized as functionally responsive to BCR triggering but it has been shown that 
a sizable fraction of CLL patients indeed demonstrate a leukemic clonal expansion of 
B cells that have anergic features (Cambier et al., 2007; Gururajan, 2014). In mice, 
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anergized B cells were characterized by low levels of IgM with no effect on IgD 
expression, elevated basal intracellular calcium concentrations and subsequent 
constitutive phosphorylation of ERK1/2 and the nuclear translocation of NF-ATc1 in the 
absence of AKT activation. Such features are also seen in a subset of CLL patients 
that corresponds with their indolent clinical presentation (Darwiche et al., 2018). 
However, it has been reported that this biochemical program is not permanent and CLL 
cell anergy can be reversed experimentally by inhibiting the signaling molecules, in 
vivo, as well, in vitro, and BCR responsiveness can be restored (Packham et al., 2014). 
This feature of anergic cells is more evident in M-CLL/Zap-70 negative cases, and more 
importantly, the reverted anergic state of B cell is followed by apoptosis induction that 
may open novel therapeutic avenues (Guarini et al., 2008; Apollonio et al., 2012; 
Darwiche et al., 2018).  
1.11 Toll like receptors as a part of CLL microenvironment  
TLRs are a family of transmembrane pattern recognition receptors (PRRs) that play a 
critical role in early innate immune response by recognizing highly conserved structural 
motifs known as pathogen–associated microbial patterns (PAMPs) expressed by 
microbial pathogens or endogenous molecules knows as danger-associated molecular 
patters (DAMPs) released from necrotic or dying cells (Reuven et al., 2014). They are 
expressed in a variety of leucocytes such as, monocytes, macrophages, natural killer 
cells, cells of adaptive immunity, T and B lymphocytes and some non-immune cells 
such as epithelial intestinal cells and fibroblasts and play a significant role in 
inflammation, immune cell regulation, survival and proliferation (Kawai and Akira, 2011; 
Huang et al., 2018). 
TLRs are homologous to Drosophila Toll protein and to date 11 functional TLRs in 
human (TLR1-TLR11) and 12 in mice has been identified (Figure 1.11), of which TLR1, 
TLR2, TLR4, TLR5, TLR6, TLR10 and 11 are located on the cell surface and primarily 
respond to bacterial membrane or cell wall associated PAMPs. The remaining TLR3, 
TLR7, TLR8 and TLR9 are expressed in endosomal/lysosomal compartments and 
recognise nucleic acid based PAMPs from bacteria and viruses. TLR 10 is a 
pseudogene (Kawai and Akira, 2010; Rybka et al., 2016). 
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Figure 1.11. Expression of Toll like receptors (TLR) on leukocytes. Each of these TLRs 
detects different subsets of pathogens (Cognasse et al., 2015). 
TLR structure includes variable number of ligands sensing extracellular leucine rich 
repeats at their N-terminal ends and a cytoplasmic TIR (TLR-IL-1R, interleukin-1-
Receptor) homology domain. The TIR domain facilitates signaling between TLRs and 
adaptor proteins such as MYD88, TRIF, TRAM and TIRAP/MAL recruited for TLR 
signaling. The activation of TLR signaling can occur in two ways via MYD88 or through 
a MYD88 independent signaling pathway. MYD88 pathway utilized by most of the 
TLRS leads to the activation of transcription NF-κB and the MAPKs, p38 and JNK (c-
Jun N-terminal Kinase). MYD88 independent pathway is mostly employed by TLR3 and 
TLR4, and leads to the activation of both, NF-κB and IRF3 (interferon Regulatory factor 
3) causing activation of other transcription factors including activator protein 1(AP-1) 
and interferons IFN-β and α (Hua and Hou, 2013; Muzio et al., 2012). Signaling 
pathways activated downstream of these adaptor molecules promote the expression of 
pro-inflammatory cytokines, chemokines, and type I and type III interferons (Figure 
1.12). However, studies suggest that only TLR4 has shown the ability to employ 
both pathways sequentially (Barton et al., 2009). 
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Figure 1.12. Schematic diagram of TLR ligands and signalling pathways. TLR receptors 
recognize different microbial components: the heterodimer of TLR4 and MD-2 recognizes 
lipopolysaccharide (LPS); TLR2 recognizes triacyl and diacyl portions of lipoproteins together with TLR1 
or TLR6, respectively; TLR5 recognizes flagellin, a major component of flagella; TLR3 recognizes 
double-stranded RNA; TLR7 recognizes single-stranded RNA and TLR9 recognizes bacterial and viral 
DNA, the so-called CpG DNA. The signalling pathways of TLRs are mediated by selective usage of 
adaptor molecules, MyD88, TRIF, TIRAP and TRAM. MyD88 is involved in all TLR signalling except for 
TLR3. TRIF is involved in TLR3 and TLR4 dependent activation of IRF3 via IKKi/TBK1, resulting in type 
1 interferon production. TRAM is responsible for the TLR4-MyD88 dependent pathway involving 
recruitment of TRIF to the cytoplasmic portion of TLR4. TIRAP is involved in recruiting MyD88 to the 
cytoplasmic portions of TLR2 and TLR4. TLR7 and TLR9-dependent production of type 1 interferon 
requires direct interaction of MyD88 and IRF7, which occurs only in plasmacytoid dendritic cells. Nucleic 
acid-recognizing TLRs (TLR3, TLR7, and TLR9) are present in the endosome (Akira, 2011). 
 
Although TLRs provide protection against a wide variety of pathogens, inappropriate or 
unregulated activation of TLR signaling can lead to chronic inflammatory and 
autoimmune disorders. In human naive B cells, TLRs are expressed at low levels, but 
the expression of some TLRs is induced upon B-cell receptor (BCR) triggering. 
Consequently, memory B cells express several TLRs at constitutively higher levels than 
naïve B cells (McGettrik and O’Neil, 2010; Correa, 2014). 
It has been suggested that the stimulation of TLRs expressed on CLL cells could 
potentially contribute to the expansion of leukemic cells. However, several studies 
suggested that TLR-9 agonists decrease viability of CLL cells and increase 
susceptibility of CLL cells to apoptosis in cell culture (Rozkova et al., 2010). Ngo et al. 
(2010) reported that MYD88 related oncogenic mutations are highly recurrent in B cell 
malignancies and are detected in 29% of diffuse large B cell lymphoma (DLBCL) and 
in 36% of primary central nervous system of lymphoma cases ((Montesinos-Rongen et 
al., 2011).   It was also found that TLRs are involved in transmitting signals via MAPK 
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and P13K in malignant cells during carcinogenesis (Bhai et al., 2017).  A recent study 
indicated that ibrutinib is an effective inhibitor in blocking TLR and BCR signaling in 
CLL cells (Herman et al., 2015). 
TLLs are heterogeneously expressed in CLL cells. CLL cells showed a variable 
expression among different CLL samples with high expression of TLR7 and 
intermediate expression of TLR1, TLR 6 and TLR10 and low expressions of TLR2, 
TLR4 and TLR 8 and TLR9 (Arviniti et al., 2011)). Barcellini in 2014 reported that CLL 
patients with low expression of TLR4 displayed higher risk of disease progression and 
a higher incidence of autoimmune complications (Barcellini et al., 2014). 
However, information about various TLR function on CLL cells is scarce, and we are 
the only group studying the importance of the patterns of CD180 expression and 
signalling in CLL. Our interest for this receptor was triggered not only by its function as 
an environmental sensor, but also due to its possible immunonmodulatory effect on B 
cell apoptosis. In a seminal paper published in 1996, Yamashita et al, demonstrated 
that priming of murine B cells with anti-CD180 (RP105) antibodies sensitised them for 
anti-BCR (IgM) induced apoptosis. This finding opened opportunities for the 
development of new therapeutic approaches for CLL using combined stimulation of 
CD180 and BCR. 
1.12 CD180/RP105 toll-like receptor 
CD180 and its murine analogue radiation protection 105 (RP105) are type 1 membrane 
associated orphan receptors which were originally identified as B cell surface 
molecules mediating activation, proliferation and differentiation and were later 
recognized as a TLR homologue. Valentine et al, in 1988 identified CD180 by a 
monoclonal antibody (mAb) designated Bgp95. Later, in 1995 Miyake et al., 
demonstrated that anti-RP105 mAb in splenic murine B cells promote B cell 
proliferation as well as resistance against radiation and dexamethasone induced 
apoptosis.  
CD180 shares 74% sequence homology with RP105. CD180 expression is restricted 
to antigen presenting cells including B cells, monocytes/macrophages and dendritic 
cells (Miyake et al., 1995). However, on B cells, it is seen mostly on naive B cells in 
mantle zone with minimum or no expression in the germinal centre cells (Otipoby et al., 
2002). The human CD180 gene is located on chromosome 5q12. CD180 has structural 
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similarities with other TLRs, particularly with TLR4. The structure of CD180 has an 
extracellular portion that consists of tandem repeats of leucine rich motifs and a 
cytoplasmic tail domain responsible for cell adhesion or receptor ligand interaction 
(Ogata et al., 2000). The extracellular leucine rich repeats (LRR) is attached to a 
secretory molecule MD-1 and together they form a complex CD180/MD-1 (Figure 1.13). 
CD180/MD-1 working in conjunction with TLR4/MD-2 complex regulates B cell 
recognition and signaling of lipopolysaccharide (LPS), a membrane constituent of Gram 





Figure 1.13. Schematic model of CD180 structure. The extracellular part has tandem leucine 
rich repeats (LRR) with cysteine residues at the end. The cytoplasmic tail consists of 6 amino acids that 
aid in receptor/ligand interaction. LRR is attached to a satellite molecule MD-1 and forms a complex 
CD180/MD-1. 
 
CD180 has 61% structure similarities with TLR4 at the extracellular portion with 
conserved cysteine residues, but differently from TLR4 does not posess intracellular 
TLR –like domain. MD-1 is required for efficient expression of RP105 as demonstrated 
by Nagai et al. (2002), since MD-1 deficient mice showed impaired LPS induced B cell 
proliferation, antibody production and CD86 upregulation. To date no natural ligand of 
CD180 has been identified, and it is assumed that CD180 has to utilize other receptors’ 
pathways to propagate intracellular signals (Chaplin, 2011). 
However, TLR4/MD-2 and CD180/MD-1 appear to utilize two distinct signaling 
pathways. CD180/MD-1 complex following binding with LPS activates Lyn kinases 
RP105-MD-1 
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leading to CD19 phosphorylation whereas TLR4/MD-2 complex binding with LPS 
triggers both MYD88/IRAK pathway and MYD88 independent (TIR) domain pathway to 
activate JNK and NFκB (Antoz et al., 2009; Chappel et al., 2014). 
Multiple studies have related expression of CD180 with a range of diseases such as 
systemic lupus erythematous (SLE), rheumatoid arthritis (Koarada et al., 2010) and, 
more recently identifying it as a first immunological marker for marginal zone lymphoma 
MZL (Rousse et al., 2014). Our group has demonstrated that CD180 is expressed 
heterogeneously on CLL cell. Whilst the majority of normal B cells expressed high 
density of CD180, only 60% of CLL samples, preferably M-CLL, expressed CD180 in a 
clonal manner (Porakishvili et al., 2005). Their follow up study demonstrated that out of 
these 60% CLL clones that expressed CD180, only half responded with activation and 
proliferation, when stimulated with anti-CD180 monoclonal antibody, delineating 
responder and non-responder CLL cells (Porakishvili et al., 2011). Our group has 
reported that following CD180 stimulation, a strong upregulation is seen in the 
phosphorylation of ZAP70, p38MAPK, ERK and AKT protein kinases in normal B cells 
as well as in responder CLL cells which is in line with the pro-survival behaviour of CLL 
cells (Chiorazzi and Ferrarini, 2005).  
1.13 Interaction between CD180 and BCR s (IgM/IgD) 
The two BCR receptors, IgM and IgD are present on the surface of most peripheral B 
cells in mice, humans and variety of other species (Noviski et al., 2018). All immature 
cells express IgM on their surface but not IgD, but mature B cells express both BCRs. 
Despite the fact that IgM-mediated signalling has been at the centre of CLL research 
for many years, the data about the role and the function of IgD on CLL cells are 
controversial. Likewise, little has been reported on the outcomes of the combined 
stimulation of B cells through the CD180 and BCR (Figure 1.14). Coligation of CD180 
and an autoreactive BCR leads to activation and proliferation of B cells and up-
regulation of co-stimulatory molecules, turning them into more efficient APCs. B cells 






Figure1.14. Functional relationship of CD180 and BCR promote B cell activation and 
differentiation. Expression of activation induced cytidine deaminase (AID) is directly induced by TLR 
signals (modified from Claes et al., 2015).  
 
Our group has demonstrated a functional relationship between CD180 and sIgM 
showing that together they contribute to the activation and survival of CLL cells 
(Porakishvili et al., 2011). Since CD180 does not have a functional cytoplasmic 
signaling domain, it might associate with other surface receptors for downstream 
signalling. Indeed, further investigation of CD180 and sIgM functional relationship 
through IgM-mediated signaling pathways in CLL indicated that CD180 engagement 
strongly affects the sIgM signalling pattern and can redirect it from pro-survival to pro-
apoptotic pathway (Porakishvili et al., 2015). This involved rewiring sIgM-mediated 
signalling pathway from PI3K/AKT to p38MAPK in CLL cells, but not in normal B cells 
(Porakishvili et al, 2015). Since CLL cells have tendency to resist apoptosis, in 
particular through activation of sIgM-mediated survival, this data opens avenues for the 
development of new modes of treatment of CLL.  
Despite all available information on the structure and high density of expression of IgD 
as a BCR component on B cells, the exact and unique role of IgD is still unknown. 
Some studies suggested that IgD functions as an optimized surface receptor improving 
and regulating B cell recruitment by an antigen. (Roes and Rajewsky, 1993; Hobeika, 
2016). It was shown that IgD in mice can substitute for IgM in case of a loss of IgM 
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(Lutz et al., 1998; Hobeika 2016). Previous studies have suggested that (surface) IgM 
and sIgD are quantitatively transmitting different downstream signals on normal B cells 
and on CLL cells (Packham and Stevenson, 2010). IgM and IgD are organized 
differently on CLL B cells where IgM forms larger and more clusters than IgD as a result 
the birth rate of CLL cells is more in the proximity of IgM than IgD (Mazarello et al., 
2017). IgD expression is absent on immature cells, low on transitional B cells and the 
highest on mature follicle B cells. However, the relevance of this differential expression 
of IgM and IgD BCR in CLL is still unclear. On the other hand, the tight regulation of 
both IgM and IgD expression in B cells and its conservation as seen in mice and 
humans suggests that IgD along with IgM may perform distinct functions that are 
specific for the relevant developmental stages in normal B cells as well as in malignant 
CLL cells (Ubelhart et al., 2015). 
Thus far, the pattern of expression and the outcome of IgD interaction with CD180 have 
not been investigated. Following the suggestion made by Hecken et al, that sIgD might 
be transmiting a different signal to sIgM signal in CLL cells, it became necessary to 
study CD180 interaction with sIgD not only to understand its role in CLL but also bearing 
in mind the possible therapeutic intervention through CD180 and sIgD in CLL (Hacken 












Interaction between signalling pathways of CD180, and sIgD a B cell receptor, 
contribute to the regulation of survival and apoptosis of CLL cells. 
Aims and Objectives  
The aim of the project was to characterise the expression and signalling patterns of 
CD180 and IgD in CLL cells. 
The following objectives were identified to achieve the aims of the project. 
 
1. To identify correlations between CD180 expression patterns and established 
prognostic indicators in CLL 
 
2. To assess the interaction between CD180 and sIgD-mediated signalling 
pathways in CLL involving protein kinases BTK, AKT and p38MAPK 
 
3. To assess and effect of CD180 and IgD engagement on survival or apoptosis 
of CLL cells, following single or combined engagement of sIgD and CD180 
 
4. To determine CD180 expression in CLL cells in stimulated and unstimulated 
cell cultures in correlation with signalling patterns 
  
























Material & Methods 
2.1 Patients  
Peripheral blood samples of 60 CLL patients aged 55 to 85 years under the care of 
Professor Amit Nathwani were collected from University College Hospital after informed 
consent and ethical approval UCL/UCLH NHS REC 08/H0714/16. The Material transfer 
agreement (MTA) between the University of Westminster (UoW) and UCH was 
obtained from the ethical committee of the University of Westminster. 
All the patients included in this study were either newly diagnosed or repeat patients 
who were untreated for 6 months prior to the study. At the time of diagnosis these 
patients had highly diverse WBC count (from 20 -100 x109/L) and at Binet stages A 
(40), B (15) and C (5). 
Formalin-fixed, paraffin wax embedded (FFPE) CLL lymph node (LN) and normal tonsil 
sections stored at St Bartholemew’s Cancer Institute, Queen Mary University of 
London, under the care of Dr Sergey Krysov were analysed for CD180 expression on 
the premises of QMUL as a part of ongoing collaboration. 
2.2 Isolation of peripheral blood mononuclear cells (PBMC) 
PBMC were isolated using Histopaque-1077 (Sigma Aldrich, UK). Blood samples were 
diluted 1:1 with Hank’s Balanced Salts Solution (HBSS, Sigma, UK).  Three ml of 
Histopaque was added to centrifuge tubes and diluted blood was layered on the top. 
Tubes were centrifuged for 30 minutes, at 400 xg at room temperature (5810R 
centrifuge, Eppendorf, UK). PBMC were collected by aspiration of the interphase using 
a sterile Pasteur pipette and transferred into new centrifuge tubes. The collected cells 
were washed twice with 5 ml HBSS at 4°C for 10 minutes, by centrifuging at 200 xg. 
The supernatant was removed, and cell pellet vortexed and re-suspended in 1 ml 
RPMI-1640 (Roswell Park Memorial Institute 1640, Sigma, UK) supplemented with 
10% v/v Foetal bovine serum (FBS, Sigma Aldrich, UK).  
The viability of purified cells was checked with Tryphan blue which was 95 to 98 %v/v. 
The number of cells present in a known volume of a sample were estimated using 
haemocytometer (Millipore, UK). The cell suspension was introduced to a known space 
of known depth (0.1mm) beneath a cover slip and counted within a grid of area 1mm2.  
This gives the number of cells per 0.1mm3 or.  0.1µl. Multiplying by 10 gives the number 
of cells per µl and multiplying by 10,000 gives the number of cels per ml. Here the 
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concentration of PBMC was adjusted using RPMI-1640 medium according to the 
experimental protocol’s requirements such as 1x106 /ml. 
2.3 Immunophenotyping of CLL cells 
200µl PBMC suspension at a concentration 1x106/ml were placed in the wells of 96 
well round-bottom microplates (Corning, Costar, and USA) and centrifuged at 200 xg 
for 5 minutes at 4ºC. The supernatants were discarded, and pellets vortexed to 
resuspend the cells. 20 µl human Immunoglobulins (Ig) (ImmunoReagents, USA) at a 
concentration 2 mg/ml were added into each well to block Fc receptors and the 
microplate was incubated for 30 min on ice. The microplate was centrifuged for 5 
minutes at 200 xg at 4°C and supernatants discarded. After vortexing, 20µl of 
unconjugated primary mouse monoclonal antibodies (mAbs) at a final concentration of 
20ug/ml were added into each designated well, whilst purified mouse IgG1 was used 
as isotype control: the antibodies used were anti-CD180, anti-IgM, anti-CD79b, anti-
CD38, anti-CD86, anti-CD40 (all from BD Biosciences, UK), and anti-IgD (Sigma 
Aldrich UK), all of the IgG1 subclass. After incubation on ice for 30 minutes, the cells 
were washed twice with HBSS for 5 minutes at 200 xg at 4ºC.The supernatant was 
removed and the microplate vortexed. Cells were then treated with 20µl of FITC 
(fluorescein isothiocyanate)-conjugated polyclonal rabbit anti-mouse immunoglobulin 
F(ab) 2, (Dako, UK) as a secondary antibody diluted at 1:15 in HBSS and incubated on 
ice in the dark (photosensitive antibody conjugate) for 30 minutes. After 30 minutes the 
cells were washed twice as above, the supernatant discarded, and the microplate 
vortexed. To block any unused rabbit anti-mouse F(ab’) sites, the cells in each well 
were treated with 20µl of mouse serum at a dilution 1:15 in HBSS (Dako, UK) and kept 
for on ice for 30 minutes in the dark. The cells were centrifuged for 5 minutes at 4ºC at 
200 xg, supernatant discarded and microplate vortexed.  
In separate experiments, direct staining of freshly isolated PBMCs in RPMI medium 
was performed using 20µl of FITC-conjugated mouse anti-human CD79a (Ancell, USA) 
at a dilution of 1:25 and 5µl of undiluted FITC-conjugated mouse IgG (BD Biosciences, 
UK) as isotype control were used. Cells were incubated on ice in the dark for 30 
minutes, washed twice with HBSS as above, supernatant was discarded and plate 
vortexed.  
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All cells were further stained with 5µl of anti-human CD19 PE-Cy5 (phycoerytherin 
cyanine 5)-conjugated mouse mAb and 5µl of anti-human CD5-PE conjugated mouse 
mAb (both - BD biosciences, UK), incubated on ice in the dark for 30 minutes, washed 
twice with HBSS as above, supernatant discarded and microplate vortexed.  
For the assessment of intracellular expression of ZAP70 protein kinase PBMCs at a 
concentration 1x106 cells/ml were treated first with 5µl of PE-Cy5 mouse anti human 
CD19 on ice for 30 minutes in the dark. Cells were washed twice, vortexed and treated 
with 50µl of Fix and Perm kit medium A (Invitrogen, USA) for 15 minutes in the dark at 
RT. Fix and Perm kit stops the cells reaction at that stage by fixing them (A) and then 
Perm reagent (B) permeabelizes the cells for intracellular staining .The cells were then 
pelleted, the supernatant discarded, the cells washed once as above, and cells were 
treated with 50µl of medium B for 15 minutes in the dark at RT. The supernatant was 
removed following centrifugation and cells were resuspended by vortexing. 5ul of FITC 
conjugated mouse IgG1 isotype control or 5ul of FITC conjugated anti-Zap-70 IgG1 
mAb (both BD Biosciences, UK) were added to the designated cells, incubated for 30 
minutes on ice in the dark and washed twice as above. 
In the case where samples were analysed immediately on the Cyan flow cytometer 
(Beckman Coulter, UK) 200µl of HBSS were added into each well after two washes 
and samples were run on flow cytometer. In other cases, 200µl of 2% v/v 
Paraformaldehyde (PFA, Biolegend, USA) were added to each well and stored at 4ºC 
(no more than for 4 days for surface receptors or 24hr for intracellular receptors) before 
flow cytometry. 
The results of the flow cytometry analysis were expressed as percentages of positive 
cells vs isotype control as well as antibody relative binding sites/cells (RBS/cell) as 
previously described (Guyre et al., 1989; Porakishvili et al., 2005). The latter reflects 
the density of the expression of surface molecules, assessed by indirect 
immunophenotyping. It was determined by comparison of mean fluorescence 
intensities of each sample to a standard curve generated with fluorescent microspheres 
using especially designed Excel template. We consider cells positive for a marker with 
RBS/cell more than 500 (Porakishvili et al, 2005). Percentages of positive cells were 
calculated using flow cytometry histograms.  
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Based on the analysis CLL cells were categorised as CD180+ or CD180-. CD180+ and 
IgD+ cells were selected for further experiments on signalling and apoptosis. 




























Figure 2.1a: Representative flow cytometer images of the indirect staning using dot 
plots, histograms and overlays. The purified PBMCs were stained for CD180 and IgG1 risotype 
control as described above and the flow cytometry data was analysed using Summit 4.3 software CLL 
cells; (A) Histogram of the isotype control IgG1 (5%); (B) Histogram of CD180+ CLL cells (84%); (C) 
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Figure 2.1b: Representative flow cytometer images of the indirect staning using dot 
plots, histograms and overlays. The purified PBMCs were stained for IgD receptor and isotype 
control IgG1 as described above and flow cytometry data was analysed using Summit 4.3 software CLL 
cells; (D) Histogram of the isotype control IgG1 (5%); (E) Histogram of IgD+ CLL cells at (87%); (F) 
Overlay plot of D (RED) and E (GREEN). 
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Figure 2.1c: Representative flow cytometer images of the direct staning of CD79a using 
histograms and an overlay. The purified PBMCs were stained for CD79a and isotype control IgG1 
as described above and flow cytometry data was analysed using Summit 4.3 software.  (A) Histogram 
of the isotype control IgG1 (5%); (B) Histogram of CD79a+ CLL cells (68%); (C) Overlay plot of A (RED) 
and B (GREEN). 
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Figure 2.1d. Representative flow cytometer images of the direct staining of Zap-70 using 
histograms and an overlay. The purified PBMCs were treated with PE Cy5 CD19 and Fix and Perm 
Medium A & B and stained with FITC conjugated IgG1 or anti- Zap-70 mAb as described above and flow 
cytometry data was analysed using Summit 4.3 software. (A) Histogram of isotype control IgG1 (10%); 

























Overlay of FITC IgG1 and Zap-70 
 54 
2.3 Assessment of the phosphorylation of intracellular protein kinases (PK) and 
CD79a 
200l CD180+sIgD+ CLL samples at a concentration 106/ml in RPMI-1640 medium 
supplemented with 10% FBS, were placed in the wells of a 96 well flat bottom 
microplate (Corning, Costar, USA). The cells were then stimulated with 8μl of sodium 
azide free anti-CD180 mAb (BD Biosciences, UK) at a final concentration 20 μg/ml for 
20 minutes alone or with 8ul of goat anti-human IgD F(ab’)2 (Southern Biotech, 
Birmingham, USA) at a final concentration 20 g/ml incubated for 10 minutes at 37°C 
in 5% CO2 incubator (Galaxy S, Uk).  
In separate experiments for combined stimulation 8μl of anti-CD180 was added first, 
and cells incubated for 20 minutes and then 8ul of anti-IgD was added and incubated 
for further 10 minutes. No antibodies were added to the control wells termed as 
unstimulated. 
Following stimulation, the cells were transferred to 96-wells round bottom microplate, 
pelleted at 200 xg, 4°C, for 5 minutes and supernatant removed. Cells were washed 
twice with HBSS as before and stained with 5µl of PE-Cy5 conjugated mouse anti-
human CD19 mAb. After 30 minutes incubation on ice in the dark, cells were washed 
twice with HBSS, fixed and permeabilised using Fix/perm kit as described above in 
section 2.1. Following reaction with Fix/perm kit cells were washed twice at 200 xg for 
5 minutes at 4°C and were stained with mAbs raised against human phosphorylated 
protein kinases: phospho-p38MAPK mouse Alexa Fluor® 488 conjugate (Cell signalling 
USA, New England Biolabs Ltd, UK), phospho-AKT Rabbit Alexa Fluor® 488 conjugate, 
(Cell signalling USA, New England Biolabs Ltd, UK), phospho-BTK mouse Alexa Fluor 
® 647 conjugate (BD Biosciences, UK) and maintained for 30 minutes in the dark at RT. 
Following incubation cells were washed twice with HBSS.   
In separate experiments of CD79a signaling, after fixation and permeabilisation of 
PBMCs, 20µl of anti-phospho-CD79a unconjugated rabbit antibody (Tyr182) (Cell 
signaling, USA) were added to stimulated and unstimulated PBMCs and incubated on 
ice for 30 minutes in the dark. Following twice washing with HBSS as above, and 
supernatant discarded, stimulated and unstimulated cells were stained with 20µl of goat 
anti-rabbit Ig secondary antibody conjugated to FITC (BD Biosciences, UK). Following 
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incubation, cells were again washed twice in HBSS to remove any unwanted reagents 
and cell debris. 
All cells to be analysed immediately were resuspended in HBSS to run on flow 
cytometer or fixed with 200ul 2% PFA and stored in the dark at 4°C to be analysed 
later, within 24hr. The results were assessed as percentages of positive cells in 
stimulated and unstimulated cultures inside gated CD19+CD5+ cell population 
















Figure 2.2: Representative flow cytometer images of histogram and overlay of 
phosphorylation of p38MAPK protein kinase in stimulated and unstimulated CLL cells 
following stimulation with anti-CD180 and anti-IgD. Purified PBMCs were stimulated with anti-
CD180 or anti-IgD or both mAbs sequentially as described above in section 2.3. Control samples were 
left unstimulated. Cells were washed and stained with anti-CD19 and anti-CD5 mAbs, fixed, 
permeabilised, and treated with anti- phospho p38MAPK Alexa flour 488 conjugate mAb as described 
above. The results were analysed by flow cytometry and Summit 4.3 software and expressed as 
percentages of positive cells inside gated CD19+CD5+ population. (A) Histogram representing 
p38MAPK+CD19+CD5+ unstimulated CLL cells (25%); (B) Histogram representing 
p38MAPK+CD19+CD5+ CLL cells upon anti-CD180 stimulation (99%); (C) Histogram representing 
p38MAPK+CD19+CD5+ CLL cells upon anti-IgD stimulation (98%); (D) Histogram  representing  
p38MAPK+CD19+CD5+ CLL cells upon sequential anti-CD180 and anti-IgD stimulation (99%); (E) 
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2.4 Assessment of apoptosis of CLL cells 
200l of CD180+sIgD+ CLL samples at a concentration 106/ml in RPMI-1640 medium 
supplemented with with 10% FBS, were placed in the wells of a 96 well flat bottom 
microplate (Corning, Costar, USA). The cells were then stimulated with 8μl of sodium 
azide free anti-CD180 mAb (BD Biosciences, UK) at a final concentration 20 μg/ml or 
with 8ul of goat anti-human IgD F(ab’)2 (Southern Biotech, Birmingham, USA) at a final 
concentration 20 g/ml and incubated for 24h at 37°C in 5% CO2 incubator. In separate 
experiments for combined stimulation, 8μl of anti-CD180 was added first and incubated 
for 20 minutes and then 8ul of anti-IgD was added and incubated for 24h. No antibodies 
were added to the control wells termed as unstimulated. 
After 24 hours of incubation, cells were transferred into wells of a round-bottom 
microplate, washed twice as described before and stained with 5µl of PE-Cy5 
conjugated mouse anti-human CD19 mAb. After 30 minutes of incubation on ice in the 
dark, cells were washed twice with HBSS as before, vortexed and re-suspended in 
200l of binding buffer (diluted in 1:10 in deionized water) supplied in AnnexinV/PI Kit 
(Sigma Aldrich, UK). 1l of Propidium Iodide (PI, 100µg/ml in 10 mM potassium 
phosphate buffer, pH 7.4, containing 150 mM NaC) and 2 l of FITC-conjugated 
Annexin V (~50 µg/ml in 50 mM Tris-HCl, pH 7.5, containing 100 mM NaCl) were added 
immediately and incubated at a room temperature for 10 min in the dark. The working 
concentration for PI and Annexin V-FITC was optimised previously in our group. 
Following 10 minutes of incubation, samples were analysed by flow cytometry 
immediately. Viable (Ann-PI-), early apoptotic (Ann+PI-) and late apoptotic (Ann+PI+) 
cell populations have been identified inside the CD19+ gate and expressed as the 










Figure 2.3. Representative flow cytometry profile of cell populations defined by 
AnnexinV/PI staining. PBMCs were stimulated for 24hr with anti-CD180 and/or with anti-IgD mAbs 
and stained with anti-CD19, Annexin V abd PI as described above. (A)  Unstimulated PBMCs; (B) PBMC, 
stimulated with anti-CD180 mAb; (C) PBMCs stimulated with anti-IgD mAb; (D) PBMCs, stimulated with 
both, anti-CD180 and anti-IgD mAbs. R5 – Ann-PI- (viable cells); R6 – Ann+PI- early apoptotic cells; R4 
































2.5 Expression of CD180 in 24, 48, and 72 hours long PBMC cultures  
200µl of IgD/IgM positive PBMCs at a concentration 106/ml in RPMI were distributed 
into wells of 96 flat bottom sterile microplate. Goat anti-human IgD or goat anti-human 
IgM F(ab′)2 (Southern Biotech, Birmingham, USA) or both were added to some wells in 
duplicates while some of the wells were left unstimulated. The microplates were kept 
for incubation for 24 hr, 48hr and 72 hr at 37ºC in 5% CO2 incubator. PBMCs, ex vivo, 
were used as zero-hour controls for the modulation experiments. 
Stimulated cells as well as 0-hour control ex vivo cells cells were transferred to 96 round 
bottom microplates and centrifuged for 5 minutes, 200 xg at 4ºC and supernatant 
discarded. Cells were washed twice in HBSS, vortexed and stained with 5µl PE-Cy5 
mouse anti -human CD19 as described above.  5µl of PE-conjugated mouse IgG1 
isotype control or PE-conjugated mouse anti-human CD180mAb were also added to 0 
hours, stimulated or unstimulated wells and left for incubation for 30 minutes in the dark 
on ice. After incubation, the microplate was centrifuged, the cells washed twice with 
HBSS as above and supernatants discarded. Cells were vortexed and resuspended in 
HBSS or PFA and analysed by flow cytometry. The modulation (increase or decrease) 
of the expression of CD180 on CD19+ cells following 24 hours and 48 hours and 72 
hours stimulation, compared with unstimulated cultures and 0 h control, were measured 
as percentages of CD180+cells as well as Mean fluorescence intensity (MFI) versus 












Figure 2.4: Representative flow cytometry images of dot plots, histograms and the 
overlay of phenotyping by direct staining for CD180 expression on PBMCs from CLL 
cells. CLL cells were stimulated with anti-IgM and anti-IgD F(ab′)2 and controls were left unstimulated 
for 24hrs, 48hrs and 72hrs. Cells were then washed and stained with PE-Cy5 conjugated anti-CD19 mAb 
and PE-conjugated mouse IgG1 isotype control or PE-conjugated mouse anti-human CD180mAb. The 
modulation of the expression of CD180 on CD19+ cells following 24 hours and 48 hours and 72 hours 
stimulation, compared with unstimulated cultures was analysed by flow cytometry. (A)Dot plot of live 
cells with gating ;(B) Gated CD19+ B Cells ;(C)Histogram representing negative population of cells (10 
%);(D) Histogram representing inceased expression of CD180+ cell in IgM stimulated 
cells(89%);(E)Histogram representating increased expression of CD180+cells in IgD stimulated 
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2.6 Fluorescence in situ hybridization (FISH)  
FISH analysis was carried out to determine possible correlations between the 
expression of CD180 and known chromosomal aberrations in CLL. The CLL samples 
utilized for FISH experiments were same as used in phenotyping, signaling and 
aopotosis experiments.  All blood samples were obtained from University College 
Hospital after informed consent as mentioned in section 2.1. 
Chromosome and nuclei preparations for FISH analysis were obtained by seeding 0.5 
ml of peripheral blood in 10 ml of pre-warmed KREAvital Lymphocyte Karyotyping 
Medium (KREATECH Diagnostics, Leica Biosystems, UK) in a 25 cm2 sterile flask 
(Thermo Fisher Scientific, Denmark). The blood cultures (at least 2 replicates per 
patient sample) were incubated at 37°C/ 5% CO2 for 72 hours. The cell cultures were 
then pelleted, and supernatant removed. Pre-warmed Hypotonic Solution Potassium 
Chloride (KCl, 0.075 M) (Life Technologies, UK) was added slowly and cells were left 
to incubate for 10 minutes at room temperature in sterile conditions. After further 
centrifugation, the pelleted cells were chemically fixed with cold Carnoy fixative (3:1 
Methanol/Acetic Acid). Slides for microscopy observation were prepared by dropping a 
small amount of the fixed cells with a Pasteur pipette onto the slides and allowed to dry 
at room temperature. A first assessment of quality of chromosome preparations was 
performed by Giemsa staining (Invitrogen, Germany) and bright light microscopy 
analysis. 
FISH analysis was undertaken using the following dual-colour (Platinum Bright™550 / 
Platinum Bright™495) probes: DLEU1 (KBI-10102), ATM (KBI-10103), TP53 (KBI-
10112) (Kreatech Diagnostics, Leica Biosystems, UK), corresponding respectively to 
the following chromosomal lesions: del13q14.3; del11q22 and del17q13. Each of the 
probes also contain a built-in control to centromeric/ telomeric sequence. Hybridization 
was carried out as per manufacturer’s instructions. Specifically, to visualise and assess 
copy number of specific DNA sequences on chromosomes and nuclei, slides were 
denatured in 70% Formamide (Sigma-Aldrich, UK) / 2xSSC (saline-sodium citrate, 
Sigma-Aldrich, UK) buffer at 72°C for approximately 1 minute 50 seconds (±10 
seconds) and then dehydrated in ice cold ethanol series (70%, 90% and 100%) for two 
minutes in each. The slides were air dry. FISH probes were denatured separately by 
incubating the probes at 90°C for approximately 9 minutes 50 seconds (±10 seconds). 
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The denatured probes were then applied to the denatured, air dried chromosomes, 
followed by application of 22x22 mm glass coverslips sealed with Fixogum (rubber 
cement) and incubation at 37°C in a humidified chamber. After 24-48 hours, the 
coverslips were removed, and the slides were washed using 2xSSC, 
0.1 Tween-20 and 0.4xSSC 0.1 tween-20 (Sigma Aldrich, UK), for 2 and 1 minutes 
respectively at room temperature. The slides were then dehydrated in ethanol series 
(70%, 90% and 100% ethanol) for approximately 1 minute each, allowed to air-dry and 
finally stained and mounted with Vectashield with DAPI (4’6’-diamidino-2-
phenylinodole) (Vector Laboratories Vector Shield) The expected fluorescent pattern 
for normal cells would be two green-two red signals, while cells with deletions of either 
DLEU or ATM or TP53 would present with and 1 red -2 green signals. 
The slides were examined on a dedicated FISH workstation housed at UCL Institute 
for Women’s Health, consisting of an Olympus BTX40 microscope powered by Sola 
light engine coupled with a Digital Scientific Camera (A3472-06) with the Smart Capture 
3 software. Image processing and analysis were performed using ImageJ software. 
ImageJ is image processing programme designed for analysing scientific 
multidimentional images. Here ImajeJ was used to calculate the number of nuclei with 
or without deletions seen under microscope. FISH data processing cut-off points were 
determined using the approach previously suggested (Wolff et al., 2007). Values 
obtained were rounded up, the minimum number of scored nuclei was set at 50 (Wiktor 





Figure 2.5. Fluorescence in situ hybridisation (FISH) representative images for 
the patient sample 
The slides were prepared as above and hybridized with the fluorescent probes DLEU1 (KBI-10102) 
designated for the chromosomal lesion del 13q14.3 and labelled with Platinum Bright™550 (red). The 
control probes for centromeric regions were labelled with Platinum Bright™495 (green). Nuclei were 
counterstained with DAPI (blue). 
(Image A) demonstrates that both 11q.22 alleles are intact; whilst (Image B) demonstrates presence of 
the double or single deletion of allele 13q14.3 in the same sample. 










and two red 
signals 
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2.7. Immunohistochemistry of lymph nodes from CLL patients  
Formalin-fixed, paraffin wax embedded (FFPE) CLL lymph node (LN) and normal tonsil 
sections stored at St Bartholemew’s Cancer Institute, Queen Mary University of 
London, under the care of Dr Sergey Krysov, cut with microtome approximately 2µm 
thick, were fully drained and placed in a 60ºC oven overnight prior to the experiment. 
Each tissue section was used in triplicate. Appropriately labelled slides were loaded 
into the track and dewaxed in xylene twice for five minutes in the fume cupboard to 
remove the paraffin wax. The slides were then transferred into a denatured alcohol 
(IMS) solution for at least 2 min followed by IMS solution supplemented with 2% v/v 
hydrogen peroxide H2O2 in order to block any residual endogenous peroxidase activity 
for 5 minutes twice. The slides were transferred into IMS solution for another 2 minutes 
and then rinsed in running tap water. The sections were outlined by a hydrophobic pen 
ImmEdge (Vectors Lab H-4000) and placed into the Tris buffered saline with Tween 
(Dako wash buffer, Dako, UK) to prevent the sections dehydration. 
Primary anti-CD180 polyclonal rabbit antibody (Merck, UK) was used at a dilution of 
1:500 in antibody diluent ZUC025-100 (Zytomed, UK) by                                                   
adding to the sections for 40 minutes, after testing three dilutions – 1:150, 1:500 and 
1:1000. The sections were washed in the wash buffer as above and goat anti-rabbit 
antibodies conjugated to polymerised (poly-) horse reddish peroxidase (HRP, Abcam, 
UK) were added for 20 minutes. The sections were washed in the wash buffer and 
ready-made SS-label (BioGenex, UK) was applied for 30 minutes and washed. DAB 
reagent was prepared according to the manufacturer’s instructions (BioGenex, UK) and 
applied to the sections for further 10 minutes.  
The sections were washed in running water, counterstained in hematoxylin for 5 
minutes and washed again in running water. The sections were further fixed, mounted 
and dehydrated using acid alcohol, Scott’s solution, IMS and xylene according to the 
standard procedure and reagents prepared in the lab. After drying in the hood, the 
sections were assessed microscopically, and images were taken for further 
assessment. Normal tonsils were the control here. 
H-score (or “histo” score) was applied to the triplicate of each tissue section, according 
to which the membrane staining intensity (0, 1+, 2+, or 3+) was determined for each 
cell in a fixed field (Hirsh et al., 2003; John et al., 2009). The percentages of cells at 
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each staining intensity level was calculated, and finally, an H-score was assigned using 
the following formula: [1 × (% cells 1+) + 2 × (% cells 2+) + 3 × (% cells 3+)]. The final 
score ranged from 0 to 300.  
The staining was performed in the Bartholemew’s Cancer Institute 
Immunohistochemistry lab by the head technician Mr Andrew Clear and UoW visiting 
researcher and alumnus Ms Kristina Zaitseva (as a part of our collaboration) and the 
images (Figure 2.6) and the H-scores were made available to me for further analysis. -  
 
 
Figure 2.6. CLL LN tissue arrays, immunohistochemistry shows variable patterns of CD180 









2.8 Statistical analysis 
The results obtained during the course of the project were analysed statistically using 
appropriate methods. Standard parametrical (Student t-test, Pearson’s correlation 
coefficient using SPSS software) or non-parametrical (Mann-Whitney U-test, 
Wilcoxon’s signed-rank test using SPSS, Spearman R correlation coefficient) tests 



















The patterns of CD180 co-expression with other prognostic 
biomarkers  
3.1 Introduction 
The clinical course of CLL is highly variable: some patients remain asymptomatic for 
many years, whereas other patients present with aggressive clinical course and require 
appropriate treatment soon after diagnosis (Chiorazzi and Ferrarini, 2010). It is 
essential to be able to predict the clinical course (indolent or the aggressive) of the 
disease for each patient as well as possible sensitivity to the available treatments in 
order to apply personalised treatment approach. Some prognostic indicators and 
biomarkers have been already integrated into medical practice such as mutational 
status of the immunoglobulin (Ig) heavy (H) chain genes (IGVH), lymphocyte doubling 
time (LDT), expression of ZAP-70 and CD38, chromosomal aberrations and genetic 
mutations. They are used to help in predicting favourable or unfavourable prognosis of 
the course of the disease (Ibrahim et al., 2001).  
IGVH mutational status has recently been found to correlate with chromosomal 
aberrations: delp17p or del11q are more likely to be associated with unmutated IGVH 
CLL cells whereas CLL cases with mutated IGVH CLL cells are more likely to acquire 
del13q associated with favourable prognosis (Mina et al., 2018). However, determining 
the IGVH mutational status requires high-priced and labour-intensive molecular 
techniques and these have a limited use in clinical practice (Rodrigues et al., 2016). 
ZAP-70 protein kinase overexpression in CLL is generally associated with poor 
prognosis (Moreno and Montserrat, 2008). According to Mina et al (2018) in over 90% 
of the CLL cases, overexpression of ZAP-70 is associated with the expression of U-
CLL, and hence unfavourable course of the disease. It has been established that the 
overexpression of CD38 on CLL cells is distinctly linked with the advanced disease 
stage, unfavourable prognosis and short-term overall survival. A study by Damle et al 
(1999) showed that the U-CLL cells have elevated expression of CD38 and are more 
likely require chemotherapy or chemoimmunotherapy.  
Chromosomal aberrations with prognostic importance in CLL  include: deletion of the 
long arm of the chromosome number 13 (del [13q]) involving DLEU1 locus, deletion of 
chromosome 6 (del[6q]), chromosome 11 (del[11q]) encompassing the ataxia 
telangiectasia mutated (ATM) locus, short arm deletion of the chromosome 17 
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(del[17p]) which involves the TP53 locus, chromosome 3 (long arm trisomy- trisomy 
3q), trisomy 8q (chromosome 8), trisomy 12q (chromosome 12) and 14q32 
translocation. Mina et al., (2018) revealed that different mutations at chromosomal level 
lead to a different clinical course: CLL cases with del17p associated with the removal 
of the TP53 locus demonstrated an unfavourable prognosis along with a short survival 
period of 32 months, whereas CLL cases with normal karyotype or del13q displayed 
favourable prognosis with longer survival periods of 10 years or more. The study also 
stated that the incidence of the del13q was the highest (55%) amongst all the different 
chromosomal abnormalities such as del11q (18%), a normal karyotype (18%) and 
trisomy 12 by 16 %.  
However, it has been commonly accepted that even within existing prognostic groups, 
individual heterogeneity of the course of the disease and responses to the available 
therapies is vast, and the stratification of individual patients in regard to the prognosis 
and optimal treatment regimen remains a big challenge. Therefore, several prognostic 
indices and models have been developed to consolidate such prognostic indicators, 
aiming to enable more definitive prediction of the clinical outcome. 
One of the new receptors which is proposed to play a role in the prognostication and 
stratification of individual CLL cases is CD180 Toll-like receptor. The heterogeneous 
expression of CD180 receptor on CLL cells with a significant correlation with M-CLL, 
was reported by Porakishvili et al. (2005). Another study by Porakishvili et al., (2011) 
demonstrated an upregulation in the phosphorylation of the ZAP70 upon CD180 
ligation. Here, I investigated if there were any correlations between the expression 
pattern of CD180 and established CLL biomarkers of prognostic importance.  
3.2 Results 
The initial analysis of CD180 with a 20% cutoff level categorised blood samples based 
on CD180 expression into two groups: CD180+ and CD180- . Samples with 20% or 
more of CD180 expression on CLL cells were considered to be positive (group A, 33 
patients) while those with less than 20% of CD180 expression were considered 
negative for CD180 (group B, 7 patients).  Further characterisation of these two groups 
of samples was performed and the results were highly heterogeneous. 
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In the 33 CD180+ samples (group A) the median level of CD180 was 58.3±23.9%. The 
expression of CD40 was characteristically high for these- cells - 93.6±30.0% (Table 
3.1). There was no statically significant correlation between the expression of CD180 
and other biomarkers. The highest correlation coefficient was seen between the 
expression of CD180 and CD38 (r =0.3), CD79b (r = 0.4), CD86 (r = 0.3) and IgD (r = 
0.4) which reflects the heterogeneity of the disease. The correlation coefficients are 
shown in Figure 3.1 for each biomarker.  
Table 3.1. Percentages of the expression of assessed biomarkers on CD180+ and CD180- 
CLL cells.  




Biomarkers MEAN Std. 
Deviation 
Group A     
CD180+ CLL CELLS 33 CD180 58.28 23.88 
  IgM 48.51 27.50 
  CD38 30.56 31.03 
  CD40 93.63 10.03 
  CD79b 36.08 23.58 
  CD86 27.70 19.96 
  IgD 36.79 29.35 
Group B     
CD180- CLL CELLS 7 CD180 6.88 3.94 
  IgM 32.69 22.64 
  CD38 10.18 9.20 
  CD40 74.57 33.02 
  CD79b 20.71 17.72 
  CD86 22.02 26.30 
  IgD 33.60 37.38 
 
Interestingly, seven CD180- samples (group B) demonstrated decreased expression of 
all the assessed biomarkers (Table 3.1), although these differences were not 
statistically significant (Figure 3.1). This trend included CD40 and IgD and IgM. Despite 
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the small number of samples in group B, higher correlations were seen between the 
expression of CD180 and CD38 and CD86  
The expression of all assessed biomarkers between groups A and B were then 


























   
 
Figure 3.1a Expression of IgD and IgM on CD180+ and CD180- CLL cells. 
PBMCs from CLL samples were immunophenotyped as described in Materials and Methods, Chapter 2. 
CLL samples were subdivided according to the levels of CD180 expression into CD180+ and CD180- 
groups using 20% cut-off. Centre line shows the mean percentages. ’n’ refers to the total number of 
patient’s cells. P (Mann-Whitney) and r (correlation coefficient) values refer to the differences between 











Figure 3.1b Expression of CD86 and CD40 on CD180+ and CD180- CLL cells: 
PBMCs from CLL samples were immunophenotyped as described in Materials and Methods Chapter 2. 
CLL samples were subdivided according to the levels of CD180 expression into CD180+ and CD180- 
groups using 20% cut-off. Centre line shows mean percentage. ’n’ refers to the total number of patients.  
P (Mann-Whitney) and r (correlation coefficient) values refer to the differences between the expression 









Figure 3.1c Expression of CD38 and CD79b on CD180+ and CD180- CLL cells. 
PBMCs from CLL samples were immunophenotyped as described in Materials and Methods Chapter 2. 
CLL samples were subdivided according to the levels of CD180 expression into CD180+ and CD180- 
groups using 20% cut-off. Centre line shows the mean percentage. ’n’ refers to the total number of 
patients.  P (Mann-Whitney) and r (correlation coefficient) values refer to the differences between the 







From Figure 3.1a, b, and c, it can be noted that CLL cells from CD180- group (RED) 
express less CD38- and CD86- compared to the CD180+ group (BLUE). We tested 
three CD180-CD38- CLL samples (as only three were available due to shortage of 
samples), for chromosomal aberrations, and all three of them were found to have 13q 
deletion (DLEU1), but no 11q deletion (ATM) or 17p deletion (TP53), as demonstrated 
in Figure 3.2 (patients B.02, P.03 and J.04). Cut-off points of each probe was 
determined to be: ATM=17.4%; DLEU1=12.3%; TP53=18.3%. The percentages of 
nuclei harboring the DLEU1 deletion were calculated for each patient as follows: 
*B.02=87.28%; *J.03=90.48%; *P.04=34.62%.   
In comparison, the other two patients, for whom the FISH data was analysed were 
CD180+: one of those (N.01) was CD38+ CD180+, the other (M.05) - CD38-CD180+ 
(data not shown in this chapter). Due to small sample size statistical analysis was not 


















    
 Percentage of Significant BioMarkers 
% 
 
ZAP-70  CD38  CD180  IgM  IgD   
Sample 
N.01  
0.3 60.61 77.82 57.30 73.67 
Sample 
B.02  
2.66 8.40 0.01 62.11 33.80 
Sample  
J.03 
72.0 0.8 0.05 23.12 58.15 
Sample   
P.04 
36.0 5.58 0.03 31.60 27.61 
Sample   
M.05 
7.86 21.65 27.86 33.47 8.22 
 
Table 3.2. Comparison of the expression of some of the surface markers and prognostic 
biomarkers in CLL samples used for FISH analysis. The percentages were obtained by 
subtracting the % of negative control IgG1 from the total percentage of individual CD markers. Here the 
IgG1 was set at 5%. CLL cells were purified and loaded with primary antibodies, stained with secondary 
antibody FITC conjugated and analysed on flow cytometer for surface markers CD38, IgM, IgD and 
CD180. ZAP70 intracellular phenotyping was carried out using intracellular staining protocol as 





Figure 3.2 a. Annotated fluorescence in situ hybridization profiles for CD180/CD38 
double-negative CLL sample B.02.  PBMCs were stimulated with PHA and processed as described 
in Materials and methods. Counted cells are shown in outlined circles. Green fluorescent probes 
delineate control centromere regions; Red fluorescent probes - critical regions. Experiments were 
repeated when Images obtained were of poor quality. A minimum number of 50 nuclei was scored for 
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Figure 3.2 b. Annotated fluorescence in situ hybridization profiles for CD180/CD38 
double-negative CLL sample P.04.  PBMCs were stimulated with PHA and processed as described 
in Materials and methods. Counted cells are shown in outlined circles. Green fluorescent probes 
delineate control centromere regions; Red fluorescent probes - critical regions. Experiments were 
repeated when Images obtained were of poor quality. A minimum number of 50 nuclei was scored for 





Chromosome critical region 13q14 
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Figure 3.2 c. Annotated fluorescence in situ hybridization profiles for CD180/CD38 
double-negative CLL sample J.03.  PBMCs were stimulated with PHA and processed as described 
in Materials and methods. Counted cells are shown in outlined circles. Green fluorescent probes 
delineate control centromere regions; Red fluorescent probes - critical regions. Experiments were 
repeated when Images obtained were of poor quality. A minimum number of 50 nuclei was scored for 




Chromosome critical region 17p13 
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In this study, blood samples from CLL patients were distributed in two phenotypic 
groups based on the expression of the CD180 receptor with the cut off for positivity 
20% (based on the data available previously in our group). The aim was to to assess 
the correlation of CD180 expression with other prognostically and biologically 
significant biomarkers, receptors and chromosomal aberrations, associated with 
favourable or unfavourable course of disease. No statistically significant correlation was 
established between the expression of CD180 and other surface markers in both 
CD180+ and CD180- subgroups. The expression of the receptors IgD, IgM and CD79b 
was heterogenous and varied from patient to patient while expression of CD40 was 
consistently high (Table 3.1). However, the CD180- group of patients was characterized 
by lower expression of almost all assessed biomarkers, the phenomenon first 
established in 2005 by Porakishvili et al. However, the CD180- subgroup had high 
CD38- cells, 85% of all cases (Figure 3.1c) indicating a possible favorable prognostic 
correlation. 
CD38 is an important prognostic biomarker in CLL that helps in determining whether 
the patient will have favourable or unfavourable disease course. A study by Damle et 
al. (1999) showed that with the cut-off of 30% CD38 can be used to distinguish between 
the CLL cases based on the prognostic differences such as requirement for 
chemotherapy. Initially, it was used as a surrogate marker for IGVH mutational status 
as the studies indicated that higher expression of CD38 was associated with unmutated 
IGVH gene status (Zupo et al., 2002; Dal-bo et al., 2009). However, subsequent studies 
have demonstrated independent prognostic significance of CD38. Although, CD38 
expression is extremely heterogeneous amongst CLL cases, it is still valid as an 
independent prognostic indicator that helps in determining the clinical course, response 
to treatment and overall survival of CLL patients (Burger and Chiorazzi, 2013). Ibrahim 
et al. (2001) demonstrated that the crucial role of CD38 in lymphocyte proliferation and 
its anti-apoptotic activities results from the up-regulation of BcL-2. It has been shown 
that CD38 ligation led to the suppression of immature B cells in the bone marrow 
microenvironment (Shanafelt et al., 2003). He et al. (2017) described that CLL patients 
with elevated expression of CD38 were characterized by the 1.92-fold increased risk of 
a relapse compared to those with lower CD38 expression. A study conducted by 
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Malavasi et al. (2011) suggested that there is an association between the high 
expression of CD38 with CLL cell proliferation and expansion leading to unfavourable 
prognosis. According to Porakishvili et al. (2005), CD180- samples showed lower 
expression of CD38 whereas increased CD38 expression was found in CD180+ CLL 
samples. 
The trend of the expression of an important prognostic indicator CD38 on CD180+ CLL 
cells and its absence on the CD180- CLL cells might suggest that the negative profile 
for both, CD180 and CD38 receptors, might be associated with favourable prognosis 
of the disease course whereas co-expression of CD180+ and CD38+ can indicate 
unfavourable prognosis.  The absence of CD38 on CD180 negative CLL cells may lead 
to increased susceptibility to apoptosis due to the low Bcl-2 expression, and decreased 
expansion potential, as indicated above. To a certain extent, this suggestion was 
supported by my data shown in Figure 3.1c that higher proportion (45%) of the CD180+ 
CLL samples expressed CD86, than in the CD180- subgroup indicating that 
CD180+CD38+ cells are more likely to be activated, although more samples are 
required to confirm this hypothesis. CD86 (B7-2) is an established B cell activation 
marker, a costimulatory molecule generally expressed by antigen presenting cells such 
as dendritic cells, B cells and macrophages. CD86 is constitutively upregulated on B-
cells and is involved in their activation. As a costimulatory molecule, CD86 can promote 
activation, growth and differentiation of B cells to lower cross-linkage by monoclonal 
antibody (Suvas et al., 2001). The certain concordance in the expression of CD180 and 
CD38 on CLL samples might serve as a potential prognostic tool to delineate CLL cases 
with favourable and unfavourable disease course and hence different approaches for 








This hypothesis has been further supported by the cytogenetic studies. It has been 
established that 80% of the CLL samples display at least one cytogenetic abnormality 
(Döhner et al., 2000; Byrd et al., 2003). In this study CLL samples were hybridised with 
commercial probes against the following chromosomal aberrations: 13q deletion 
(DLEU1), 11q deletion (ATM) and 17p deletion (TP53). Metaphase cytogenetic 
abnormalities were found in three patients with the highest frequency of del(13q) [n=3] 
and rest of the patients lacked any of the genetic aberrations. Del (13q) had either 
mono-allelic or bi-allelic loss in the examined samples. None of the samples displayed 
the del17p (TP53) or 11q deletion (ATM). Evidence of other cytogenetic lesions was 
not found in the CLL samples examined, this could be either because of experimental 
error or the patient did not have any of the cytogenetic abnormalities. This could have 
been confirmed by repeating the experiments with substantial chromosomal culture to 
reach definitive decision but at the time of submitting this thesis it was not possible due 
to shortage of samples, therefore this analysis was made on a small number of 
samples. 
In this small group of patients all samples with the DLEU1 deletion were negative for 
CD180 and CD38. One patient (B.02) was also negative for ZAP70 expression (2.66%). 
In contrast, the other two -negative for CD180 and CD38 samples were ZAP70+.  
Deletion del(13q) DLEU1 is the most common chromosomal lesion reported in CLL and 
has been associated with a favourable prognosis, good clinical outcome, better 
response to treatment and overall survival (Puiggros et al., 2014; Rahimi et al., 2017). 
According to Dal-bo et al (2009) deletion del (13q) is associated with the mutated IGVH 
genes. On the other hand, ZAP-70 expression is known to delineate U-CLL (Table 3.2) 
(Zap70 cutoff point =15%).Therefore, on this basis it was assumed that patient B.01 
was likely to have favourable prognosis as negativity for CD38, ZAP70 and CD180 
together with del (13q) should be associated with the better clinical outcome along with 
the possibility of favourable prognosis (Nabhan et al., 2015; Gomes et al., 2017) and 
better overall survival. 
However, the other two cases were more complex. These were patients with 
concordant negativity for CD180/CD38 and deletion DLEU1 but were ZAP70 positive. 
Likewise, one of the patients with normal genotype (N.01) with no chromosomal 
aberrations were CD180+ and CD38+ but negative for ZAP70 (0.3%). The 
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prognostication in such a case would remain indecisive since a seemingly “normal” 
karyotype often harbour genomic mutations associated with unfavourable prognosis 
and resistance to the therapy (Hallek, 2008; Rodrigues et al., 2016). Conversely, 
several studies stated that U-CLL samples with complex karyotype (deletion 17p or 
11qdel) cells are most likely to have unfavourable course of disease and be less 
responsive to treatments whereas M-CLL cases with ‘’normal karyotype’’ will have an 
indolent course of the disease (Rigolin et al., 2017). On one hand, the N.01 sample 
was positive for CD180 and CD38, presented with no DLEU1 mutation, which would all 
suggest favourable prognosis, on the other hand, it was negative for ZAP70 which 
indicates an M-CLL status and indolent course of disease. Unfortunately, due to small 
number of samples available, we were not able to draw conclusion, but the concordant 
pattern of CD180/CD38 expression and DLEU1 mutation appears as a promising tool 
for identifying indolent CLL course for personalized therapies.  
It would be very interesting to further assess this hypothesis, based on the information 
presented above: whether a concordance in terms of positive expression of 
CD180/CD38 and absence of the benign deletion del), all indicating an aggressive CLL 
course of disease, could outbalance the absence of ZAP70 which is a marker of 
favourable prognosis. This would evaluate the importance of the triad of biomarkers: 
co-expression of CD180 and CD38 and absence of the DLEU1 lesion as a strong 
indicator stratifying the aggressive course of the disease, independently from ZAP70 
expression often linked with IGVH mutational status (Dickinson et al., 2005). Likewise, 
concordant negativity for CD180/CD38 linked to the DLEU1 deletion, may outbalance 
the expression of ZAP70, indicating a favourable prognosis. In order to fine-tune the 
prognostic value of these patterns, the IGVH mutational status and other chromosomal 
aberrations/gene mutations would need to be determined. An approach taken to 
minimise such errors would be to conduct whole-genome sequencing for each patient 










1. Concordant presence or absence of the triad of biomarkers: CD180, CD38 and 
DLEU1 deletion may have a stratification significance for the CLL prognosis. 
2. Concordant negativity for CD180 and CD38 expression may associate with 13.1q 
DLEU1 chromosomal aberration and an indolent course of the disease.  
3. Concordant positive expression of CD180 and CD38 in the absence of DLEU1 might 






















Interaction between CD180 and IgD mediated signaling 
pathways in CLL. 
4.1 Introduction 
Recent advances in our understanding of the pathobiology of CLL have contributed to 
the development of new molecular therapies, which, together with immunotherapy, 
have been gradually replacing conventional chemotherapy in the treatment of this 
disease (Montserrat et al., 2016; Hallek, 2017). Sequencing of the B-cell receptor 
(BCR) allows categorization of CLL patients into two clinical subsets according to their 
immunoglobulin (Ig) VH genes’ mutational status, which is now used as a prognostic 
indicator of the responses to therapies and overall survival. The presence of unmutated 
IGVH genes is usually associated with the expression of zeta-associated protein 70 
(ZAP-70), which is not expressed by normal B-cells and is associated with a more 
aggressive form of CLL (Hamblin et al., 1999; Chen et al., 2005; Zhang and Kipps, 
2014). Moreover, the expression of CD38 and CD49d is also associated with an 
unfavorable prognosis. Both markers have been shown to be involved in CLL cell 
migration and proliferation (Buggins et al., 2011; Hendy et al., 2016) as discussed in 
previous chapter. 
Furthermore, it has also been established that the tumour microenvironment plays an 
important role in the pathogenesis of CLL, by providing chemokines and adhesion 
molecules that contribute to the survival and proliferation of the leukaemic cells 
(Herishanu et al., 2011; Zhang and Kipps, 2014). In addition, it also promotes the 
activation of the BCR-mediated signaling through the phosphorylation of 
immunoreceptor tyrosine-based activation motifs (ITAMs) present in CD79a and 
CD79b complex-associated proteins, leading to the downstream activation of pro-
survival signaling pathways, such as protein kinase B (AKT), extracellular signal-
regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB) pathways (Herishanu et al., 2011; Zhang and Kipps, 2014; Porakishvili et 
al., 2015). Understanding of the regulation of these signaling pathways is paramount 
for the development of BCR-signaling antagonists, which block the activation of protein 
kinases leading to the CLL cell survival and expension (Jones and Byrd, 2014). One of 
the most prominent examples are Bruton’s tyrosine kinase (BTK) inhibitor Ibritunub and 
 87 
 
phosphoinositide 3-kinase (PI3K) inhibitor Idelalisib, currently fully intergrated into 
clinical practice after showing promising results in clinical trials. However, these drugs 
are associated with several serious side effects (Jones and Byrd, 2014; Rozovski et 
al., 2014; Hallek, 2017) and hence the search continues for stratification biomarkers 
that would allow more accurate, if not precise personalized approach to the therapy. 
Several studies have demonstrated that toll-like receptors (TLR), with an important role 
in the regulation of the innate immune system, are also involved in the pathogenesis of 
CLL (Muzio et al., 2012). Different levels of expression of TLRs were found in CLL cells, 
and several studies indicated the potential role of TLRs in the modulation of CLL cell 
signaling response (Muzio et al., 2009; Rozková et al., 2010; Rybka et al., 2016).  
CD180 is an orphan receptor that belongs to the TLR family and triggers activation and 
proliferation of normal B-cells (Valentine et al., 1988; Muzio et al., 2012). It has been 
shown by our group that CD180 is expressed in approximately 60% of CLL cases and 
that its expression levels are higher in M-CLL cells (Porakishvili et al., 2005). CD180 
ligation on normal B cells and on so called responder (R) CLL cells led to even stronger 
activation, proliferation and survival of CLL cells compared to those mediated by CD40 
or rIL-4. (Porakishvilli et al., 2011).  
Further studies have shown that CD180 can either promote CLL cell survival and 
cycling via BTK/PI3K/AKT pathway or induce apoptosis via p38 mitogen-activated 
protein kinase (p38MAPK) pathway (Porakishvili et al., 2011; Gordiienko et al., 2017). 
These results are consistent with previous studies which demonstrated the ability of 
CD180 to signal in human and murine B lymphocytes (Valentine et al., 1988, Yazawa 
et al., 2003, Divanovic et al., 2007) providing the signals for B cell survival and 
proliferation (Clark et al., 1989; Roshak et al., 1999).  
Most importantly, it has been demonstrated that CD180 is able to redirect IgM-mediated 
signaling from the pro-survival BTK/PI3K/AKT to the pro-apoptotic p38MAPK pathway 
in CLL cells (Porakishvili et al., 2015) suggesting cross-talk between the signalling 
pathways operating via IgM and CD180. These findings suggest that CD180 can 
potentially be used not only as prognostic indicator, but also as a molecular target for 
the treatment of CLL patients. However, the ligand of this TLR is still unknown, and 
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further research on CD180 signaling pathways is also required (Porakishvili et al., 2011, 
2015).  
Importantly no information thus far been provided on the possible interplay between 
IgD component of BCR and CD180. As reviewed by Hacken et al. (2016), most CLL 
cells express both IgM and IgD components of BCR but signaling through these two 
isotypes leads to different functional responses in CLL cells, which are not yet fully 
understood. It has been suggested that signaling through the IgM isoform induces more 
durable signaling responses in CLL cells, usually via ERK signaling pathway, and that 
it also stimulates the secretion of C-C motif chemokine ligand 3 (CCL3) and C-C motif 
chemokine ligand 4 (CCL4), contributing to CLL cell survival and proliferation (Hacken 
et al., 2016). On the other hand, signaling through the IgD isoform seems to induce the 
activation of hematopoietic lineage cell-specific protein 1 (HS1) and the polymerisation 
of F-actin, which results in receptor internalisation and transient downstream signaling 
responses that fail to promote CLL cell survival (Hacken et al., 2016). In addition, 
previous studies have suggested that IgM is the main isoform targeted during ibrutinib 
treatment, however it has been shown that this BTK inhibitor also interferes with IgD-
mediated signaling (Hacken et al., 2015; Mazzarello et al., 2017). 
The heterogeneity of CD180-mediated signaling pathways and their interaction with 
BCR isoforms might be affected by the stability and/or modulation of CD180 expression 
on CLL cells. 
As previously reported by Porakishvili et al in 2005, CD180 is heterogeneously 
expressed on CLL cells, and about 40% of CLL samples are CD180 negative. In 
contrast, a vast majority (95-98%) of normal B cells, both CD5- and CD5+ express 
CD180 (Porakishvili et al., 2005).  
The variation in the expression of CD180 on B cells has been highlighted before. 
Koarada et al. in 2011 reported that following CD180 stimulation with mAb the 
expression of CD180 significantly dropped in PBMCs in Systemic Lupus 
Erythematosus (SLE) patients. Interestingly these stimulated CD180negcells were the 
ones spontaneously producing autoantibodies of both, IgG and IgM classes (Koarada 
and Tada, 2011). Another study reported that in murine B cells signalling through TLR7 
and TLR9 also resulted in the reduction of the CD180 expression (You et al., 2015).  
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CD180 expression levels in individual CLL samples taken from the same patients over 
a period of 24 months did not change (Porakishvili et al., 2005). However, Tsertsvadze 
et al. (2015) demonstrated that CD180 expression was significantly decreased 
throughout 0-96 hours in the spontaneous MEC1 cell culture. Hence there appear to 
be fluctuations in the expression of CD180 in the spontaneous and stimulated long-tirm 
cell cultures, whilst the ex vivo expression pattern is stable.  
Since presence of CD180 was affecting the signaling pattern of CLL cells as seen 
previously with IgM signaling (Porakishvili et al., 2015), it can be hypothesized that 
different signalling patterns of CLL cells were partially based on CD180 receptor 
turnover. Due to the established cross-talk between CD180 and the BCR, this turnover 
could be affected by the BCR ligation. 
Here the aim was to investigate the interaction between IgD and CD180 signalling 
pathways involving key protein kinases BTK, AKT and P38MAPK as indentified 
previously (Porakishvili et al.,2011;2015) for IgM-mediated signalling. Additionally, I 
also attempted to study spontaneous fluctuation of the percentages of CD180+ cells, 
as well as their modulation by the engagement of sIgD. 
4.2 Results 
Individual CLL samples exhibited a heterogeneous response to the direct ligation of 
CD180 or sIgD alone or in combination, assessed by the phosphorylation of AKT and 
p38MAPK. Our research group has previously established that individual CLL samples 
can be subdivided into four major categories, by their ability to activate signalling 
pathways in response to the CD180 ligation. These were AKT-Signalers (AKT-S), 
p38MAPK-S (p38MAPK-S), non-Signalers (NR), and a very small group of 
AKT/p38MAPK double signallers (DS) responding as normal B cells belonged to the 
DS category (Porakishvili et al., 2015). On ligation of sIgM, in our hands, almost all CLL 
samples demonstrated phosphorylation of AKT, or a lack of response, and only a small 
proportion of CLL cells (12%) phosphorylated p38MAPK (Porakishvili et al., 2015).   
In this study I have categorised CD180+IgD+ CLL samples into AKT-S and p38MAPK-
S by their responsiveness to the ligation of CD180 with mAb and studied the pattern of 
the response of these subtypes of CLL samples to anti-IgD F(ab)2 stimulatory 
antibodies. The readout comprised phosphorylation of AKT, p38MAPK and BTK protein 
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kinases.  sIgD was expressed heterogeneously on 61.5±38.9% CLL cells with an 
RBS/cell 3579±2579. The results are shown in Figure 4.1. 
 
Figure 4.1. Phosphorylation of AKT and p38MAPK protein kinases in AKT-signalers 
(AKT-S) and p38MAPK signaller (p38MAPK-S) CLL cells following stimulation with anti-
CD180mAb or anti-IgD antibodies. Ten CD180+IgD+ CLL samples were stimulated with anti-
CD180 mAb or goat anti-human IgD F(ab)2 for 20 minutes and 10 minutes respectively for sole 
stimulation. Upon stimulation, cells were treated with anti-CD19 mAb, fixed, permeabilised, and stained 
with antibodies to AKT-P (Ser473) (A) or p38MAPK-P (B) and assessed by flow cytometry as described 
in the Materials and methods. Unstimulated samples remain untreated. P values were calculated using 
the paired t-test. 
 
According to my data, individual CLL samples exhibited heterogeneous response to 





p38MAPK. However, in contrast to sIgM, in my hands, sIgD-mediated signalling 
favoured the p38MAPK pathway. Only in 3 out of 10 AKT-S, and in none of the 
p38MAPK-S CLL samples we detected an increase in AKT phosphorylation following 
sIgD ligation (Figure 4.1 A). In contrast, all p38MAPK-S and 7 out of 10 AKT-S CLL 
samples demonstrated enhanced p38MAPK phosphorylation in response to anti-IgD 
(Figure 4.1 B), leading to an increased apoptosis of CLL cells compared to unstimulated 
cell cultures (medium), assessed by early apoptotic Annexin+PI- cells from 28.5±12.9% 
up to 78.3±22.4%, n=10, p=0.00041 (Figure 4.2 B). 
Porakishvili et al. (2015) demonstrated that pre-treatment with anti-CD180 mAb of CLL 
cells redirected IgM-mediated signalling from AKT to p38MAPK pathway. To study the 
possible effect of CD180 ligation to sIgD-mediated signalling, I investigated 
phosphorylation (P) of these protein kinases in response to the sequential ligation of 
CD180/IgD. Whilst pre-engagement of CD180 did not affect the levels of AKT 
phosphorylation following the ligation of IgD in AKT-S category of CLL cells (data not 
shown), it strongly synergised with sIgD-mediated phosphorylation of p38MAPK 
(p=0.0032, Figure 4.2 A, n=10). 
BTK phosphorylation in response to CD180 or sIgD ligation across the categories of 
CLL cells was highly heterogeneous (data not shown). We therefore decided to pool 
the AKT-S and p38MAPK-S data together for both, anti-CD180 and anti-IgD 
stimulations, and the results are shown in Figure 4.3 (n=11). Whilst the response is still 
very heterogeneous and the differences between stimulated and unstimulated cultures 
are statistically insignificant, there can be seen a certain trend: in a proportion of CLL 
samples the ligation of anti-CD180, but not IgD, leads to a strong phosphorylation of 




Figure 4.2. Phosphorylation of p38MAPK protein kinases in p38MAPK signaller 
(p38MAPK-S) CLL cells following sequential stimulation with anti-CD180mAb and anti-
IgD antibodies. Ten CD180+IgD+ CLL samples were stimulated with anti-CD180 mAb for 20 minutes 
and by goat anti-human IgD F(ab)2 for 10 minutes for single stimulation. For combined stimulation 
primarily for 20 minutes with anti-CD180mAb and then with anti-IgD for further 10 minutes. Upon 
stimulation, cells were treated with anti-CD19 mAb, fixed, permeabilised, and stained with antibodies to 
AKT-P (Ser473) (A) or p38MAPK-P (B) and assessed by flow cytometry as described in the Materials 
and methods. Unstimulated samples remain untreated. P values were calculated using the paired t-test.  
 
Figure 4.3.  Phosphorylation of BTK jointly in AKT-S and p38MAPK-S categories of CLL 
cells in response to the CD180 and IgD ligation. 11 CD180+IgD+ CLL samples were stimulated 
with anti-CD180 mAb or goat anti-human IgD F(ab)2 for 20 minutes and 10 minutes respectively or with 
a sequential ligation of CD180 and IgD. Upon stimulation, cells were treated with anti-CD19 mAb, fixed, 
permeabilised, and stained with antibodies to BTK-P and assessed by flow cytometry as described in 
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Importantly, sequential ligation of CD180 and IgD seems to reduce the percentages of 
BTK-P+ cells (Figure 4.3).  
It has been previously demonstrated that CD180-mediated intracellular signalling 
transmitted via PI3K/AKT leads to the survival of CLL cells, whilst p38MAPK pathway 
favours apoptosis (Porakishvili et al., 2015). In my experiments I chose to use Annexin 
V/PI binding which allows to detect membrane-associated and nuclear events and 
identify early, and late apoptotic cells as discussed in the Material and Methods section.  
 
Table 4.1: Percentages of apoptotic cells in unstimulated and stimulated CLL cells 
following AnnexinV/Propidium Iodide staining:  n is the number of samples.  
n=16 % viable cells  early apoptosis late apoptosis Total 
Apop 
US Average % 66.19 27.94 5.87 33.81  
Stdev      % 20.96 15.53 10.66 20.96       
anti-IgD 
Stim 
Average % 50.28 43.67 6.05 49.72 
 
Stdev      % 18.66 16.75 10.76 18.66       
anti-CD 
180 Stim 
Average % 40.95 48.83 10.22 59.05 
 
Stdev      % 34.10 30.64 17.44 34.10       
anti-CD 
180+ IgD 
Average % 32.84 57.23 9.93 67.16 
 
Stdev      % 28.16 26.23 16.69 28.16 
 
As shown in Table 4.1, the levels of apoptosis were higher in CLL cells stimulated with 
both anti-CD180 and anti-IgD mAbs (67.16 %; SD ± 28.16 %) than in unstimulated CLL 
cells (33.81 %; SD ± 20.96 %) or in CLL cells stimulated with anti-CD180 (59.05 %; SD 
± 34.10 %) or with anti-IgD (49.72 %; SD ± 18.66 %) Abs alone. The statistical analysis 
showed no significant difference (p ≥ 0.05) in the percentages of viable and early/late-
stage apoptotic cells between unstimulated CLL cells and CLL cells stimulated with 
anti-CD180 mAb. However, there was a significant increase in the percentages of early-
stage apoptotic cells in CLL cells stimulated with anti-IgD mAb in comparison to 
unstimulated CLL cells (p = 0.039) (Figure 4.4). 
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Notably, there was a significant difference in the percentages of viable and early-stage 
apoptotic cells between unstimulated CLL cells and CLL cells stimulated sequentially 
with anti-CD180 and anti-IgD mAbs (p = 0.009, Figure 4.4). This indicates that the 
stimulation with anti-IgD following pre-ligation with anti-CD180 mAb favoured the pro-
apoptotic pathway in CLL cells. Most importantly there was a concordance of CD180 
and IgD-mediated apoptosis, with a combined ligation of the two receptors exceeding 
that of IgD alone (Figure 4.2B).  
Therefore, it could be concluded that sequential ligation of CD180 and IgD leads to the 
concordant upregulation in the percentages of cells with phosphorylated p38MAPK and 
those at the early stages of apoptosis. 
Figure 4.4. The percentages of early and late apoptotic cells  in unstimulated CLL cells compared 
with CLL cells stimulated with anti-IgD Abs, anti-CD180 mAb or both anti-CD180 and anti-IgD Abs. 
CLL cells were stimulated with anti-CD180 mAb for 20 minutes or goat anti-human IgD F(ab)2 for 10 
minutes, or sequentially by anti-CD180 and anti-IgD as describes previously in Materials and method 
and incubated for 24 hours at 37ºC and 5% CO2. After incubation, the cells were stained with anti-CD19 
mAb, loaded with Annexin V/Propodium iodide (PI) in binding buffer and analysed by flow cytometer. 
Mann-Whitney non-parametrical U-test was used for the statistical analysis. 
 
Further studies were carried out on the stability CD180 expression on CD180+CLL cells 
in cell cultures for 24, 48 and 72 hours. The surface expression of CD180 receptors on 





CD180+IgM+IgD-ve. Importantly, all five samples belonged to the AKT-S category, 
where AKT pathway is associated with proliferation and survival of CLL cells. 
The important immediate observation was a significant drop in the levels of the 
expression of CD180 on unstimulated CLL cells after the first 24h in culture (p= 0.003), 
with further decrease for the 48h timepoint (p=0.009) in all five CLL samples (Figure 
4.5). Four out of five CLL samples demonstrated a low plateau through the incubation 
time 48-72h apart from one sample which showed the signs of CD180 recovery. Since 
phenotypically this sample was CD180+IgM+IgD+ as were the other three, hence this 
result was considerd an artefact, albeit more samples were required for conclusive 
remarks. 
 
Figure 4.5. Percentages of 180+ CLL cells in 0-72h cell cultures. CD180+CLL samples were 
incubated for 24,48 and 72 hours unstimulated or stimulated with anti-IgM or anti-IgD F(ab)2, washed 
and stained with PE-conjugated mouse IgG1 isotype control or PE-conjugated mouse anti-human 
CD180 mAb and PE-Cy5-conjugated mouse anti-human CD19 mAb as described in the Materials and 
methods. The results were analysed using flow cytometry and Summit 4.3 analytical software and 
expressed as percentages of CD19+CD180+ positive cells. Isotype control values were subtracted. p 
values were calculated using the paired t-test. Percentages of cells binding to the isotype control antibody 
were subtracted. Ex vivo (“0” time) CD180 expression was used as a control.  
 
It appears that the application of stimulating anti-IgM or anti-IgD antibodies resulted in 
the acceleration of the downregulation of CD180, most importantly, both antibodies 
lead to a very similar drop in the CD180 expression. And this was despite of the fact 
that anti-IgM treatment resulted in the increased survival, whilst anti-IgD – mostly, in 













































Yamashita et al. in 1995 and Yamazaki et al. in 2010, observed that pre-treatment of 
murine B cells with anti-CD180 mAb led to apoptosis following ligation of surface IgM.  
Porkaishvili et al., (2015) demonstrated that the sequential liagtion of CD180 and IgM 
BCR on CLL cells led to the redirection from pro-survival BTK/P13K/AKT signaling 
pathway towards pro-apoptotic p38MAPK pathway. Here the aim was to investigate the 
interplay between signalling pathways of CD180 and sIgD BCR and assess the 
resulting levels of cell survival/apoptosis.  
As previously described by Hacken et al. (2016), most CLL cells express both IgM and 
IgD but the signaling through these two BCR isotypes leads to different functional 
responses in CLL cells, which are not yet fully understood. In fact, it has been 
suggested that the IgM isoform induces more durable signaling responses in CLL cells, 
usually via ERK pathway, and that it also stimulates the secretion of C-C motif 
chemokine ligand 3 (CCL3) and C-C motif chemokine ligand 4 (CCL4), contributing to 
CLL cell survival and proliferation (Hacken et al., 2016). On the other hand, signaling 
through the IgD isoform seems to induce the activation of hematopoietic lineage cell-
specific protein 1 (HS1) and the polymerisation of F-actin, which results in receptor 
internalisation and transient downstream signaling responses that fail to promote CLL 
cell survival (Hacken et al., 2016). Previous studies have suggested that IgM is the 
main isoform targeted during Ibrutinib treatment, however it has been shown that this 
BTK inhibitor also interferes with IgD-mediated signaling (Hacken et al., 2015; 
Mazzarello et al., 2017). In accordance with Hacken et al. (2016), my results showed 
that all CLL samples analysed were positive for the expression of IgD (84,62 %) and 
that the levels of expression of this BCR isotype were slightly but not significantly lower 
from the ones of IgM and CD180 (p > 0.05).   
It was confirmed here that ligation of CD180 alone led to heterogeneous signalling 
responses with a well-defined dichotomy to AKT-signallers (AKT-S) and p38MAPK-
signallers (p38MAPK-S) (Figures 4.1) as it had been reported previously (Porkaishvili 
et al., 2015).  In addition, my results showed that the stimulation of CLL cells with anti-
CD180 mAb led to an increase in both, BTK and p38MAPK phosphorylation levels in 
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comparison to unstimulated CLL cells, which also indicates that CD180-mediated 
signaling can either promote survival or induce apoptosis in CLL cells (Figure 4.3).  
Furthermore, Porakishvili et al. (2015) demonstrated that the stimulation of CD180+ 
CLL cells with anti-IgM mAb alone led to a significant increase in the activation of the 
pro-survival BTK/PI3K/AKT signaling pathway, which is involved in CLL cell survival 
and proliferation. In contrast, my results showed that there was a decrease in BTK 
phosphorylation levels and an increase in p38MAPK phosphorylation levels in CLL cells 
stimulated with anti-IgD mAb (Figures 4.1 and 4.3). This was accompanied by a 
significant increase in the percentages of early-stage apoptotic cells in CLL cells 
stimulated with anti-IgD mAb in comparison to unstimulated CLL cells (Figure 4.4, p = 
0.039), suggesting that, as previously proposed by Hacken et al. (2016), IgD-mediated 
signaling induces apoptosis in CLL cells. 
It has been well documented that phosphorylation of AKT is essential for the BCR-
mediated growth and survival of CLL cells (Downward, 2004; Longo et al., 2008). The 
drop in AKT-P basal levels in the AKT-S cells following CD180 ligation might indicate 
that these cells are destined for apoptosis. The role of p38MAPK-mediated signalling 
in CLL remains unclear. Activation of p38MAPK has been previously associated with 
proliferation of various cells (Okkenhaug et al., 2007; Herman et al., 2010). In CLL, 
activation of p38MAPK was reported to be involved in the regulation of cell survival and 
apoptosis (Barragan et al., 2003; Scuppoli and Pizzola, 2012). In my hands, in CLL 
activation of p38MAPK-mediated signalling pwathways was condocrdant with the 
induction of apoptosis. 
Bearing in mind possible therapeutic implications, Porakishvili et al. (2015) 
demonstrated that the pre-treatment of CLL cells with anti-CD180 mAb redirected IgM-
mediated signaling from the pro-survival BTK/PI3K/AKT signaling pathway to the pro-
apoptotic p38MAPK signaling pathway. My results showed that in CLL cells stimulated 
with both CD180 and anti-IgD mAbs, a decrease in the percentages of AKT-P+ cells 
and an increase in the p38MAPK phosphorylation levels was observed, in comparison 
to unstimulated CLL cells (Figures 4.1 and 4.2). Importantly, there was also a significant 
increase in the percentages of early-stage apoptotic cells in CLL cells stimulated with 
anti-IgD following the pre-ligation with CD180 mAb in comparison to unstimulated CLL 
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cells (p = 0.009, Figure 4.2 and 4.4). This suggests that CD180 and IgD-mediated 
signalling could synergistically induce apoptosis in CLL cells via the p38MAPK 
pathway. Thus, a strong synergism exists between CD180 and IgD mediated pathways 
in the activation of p38MAPK and the induction of apoptosis of CLL cells. 
Dramatic downregulation of the expression of CD180 on CLL cells in spontaneous 
cultures, as well as those stimulated through IgM and IgD ligation (Figure 4.5), might 
indicate receptor endocytosis (Stevenson et al., 2011). The process involves 
internalisation of ligand –receptor complexes and removal of ligands in endosomes. 
The remaining receptor either degraded or recycled back to the cell surface. The 
unexpected and intriguing result of my experiments is the spontaneous downregulation 
of CD180 in cell cultures in all five analysed samples. Internalisation of TLRs upon their 
ligation has been documented before, such as TLR4 cellular targeting and signaling via 
the formation of ligand–receptor complex involving the mechanism of endocytosis 
(Gangloff; 2012). Since CD180 is also homologous to TLR4, it can be reasoned that 
following CD180 ligation, signaling via CD180 might be recruiting a similar mechanism 
involving receptor-ligand internalisation. However, no artificial CD180 ligand (mAb) has 
been used in my experiments, and yet CD180 expression significantly decreased. 
Before more experiments are carried out on a larger number of samples, I can 
hypothesise that in these samples CD180 has been ligated, in vivo, by a putative ligand, 
and hence the rapid internalisation occurred, in vitro, without exposure to anti CD180 
in vitro. 
That CD180 expression is downregulated on activated B cells in rheumatoid diseases 
has been documented, although the mechanism of downregulation has not been 
studied (Kikuchi et al., 2008; Koarada et al., 2014). 
In my experiments, since anti-IgM and anti-IgD, both induced acceleration in the 
downregulation of CD180, this indicates interaction between BCR and CD180 at the 
very early stages in CLL cell activation, perhaps through the receptor trafficking in lipid 
rafts. Receptors trafficking and assembly in the lipid rafts has functional importance in 
intracellular signalling (Villar et al., 2016). Therapeutic antibodies such as anti-CD20 
Rituximab and anti-CD52 Alemtuzumab translocated to the lipid’s rafts accompanied 
by the increase in the intracellular Ca2+ to facilitate downstream apoptosis signaling 
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pathways (Janas et al., 2005). There is a possibility that IgM and IgD ligation triggers 
CD180 receptor co-trafficking towards lipid rafts thus causing instability in the 
expression profile of CD180 on CLL cells. Of note, all analysed sampled belong to the 
AKT-S category which initiate downstream signalling pathway BTK/PI3K/AKT following 
CD180 ligation. Interestingly, CD180 downregulation was seen following IgD ligation 
as well, despite of the activation of p38MAPK route. This indicates that CD180 
downregulation in the AKT-S category of cells is an early event of signalling leading to 
either CLL cell survival, or apoptosis 
 
4.4 Conclusions 
1. Individual CLL samples exhibited heterogeneous response to ligation alone of 
CD180 or sIgD as assessed by the phosphorylation of AKT and p38MAPK.  
2. sIgD-mediated signalling favoured the p38MAPK pathway, leading to the 
increased apoptosis of CLL cells compared to unstimulated cell cultures.  
3. Pre-engagement of CD180 synergised with sIgD-mediated p38MAPK-mediated 
pro-apoptotic signalling in CLL cells. 
4. After 24h in culture CD180 is rapidly downregulated from CLL cells, the process 






























The patterns of CD180 expression in the lymph nodes of CLL 
patients 
5.1 Introduction 
As discussed above, CLL is a lymphoproliferative disease with heterogeneous 
manifestations. It is characterized by a variable distribution of tumour mass between 
peripheral blood, bone marrow and lymphoid organs, and this is an important 
prognostic indicator. Presentation with lymphadenopathy and splenomegaly is used for 
staging and classification of the disease. Bone marrow and lymph nodes provide 
lymphoid tissue microenvironment contributing to the pathogenesis of the CLL (Burger 
et al., 2009).  Bone marrow stromal cells when added to CLL cell cultures in vitro, aid 
the survival of the tumour cells which otherwise undergo rapid spontaneous apoptosis 
(Deaglio et al., 2010). Most of the clonal evolution, survival and proliferation of CLL 
cells, occurs in specialised structures in the lymph nodes (LNs), and in the bone marrow 
(BM) called “proliferation centres” (PCs) and found in approximately 90% of CLL cases. 
The initial studies of lymphoid organs in CLL refer to the PCs as “pseudofollicles” which 
consist of loosely arranged large cells with prominent nucleoli, in contrast to true B-cell 
follicles, often surrounded by the small lymphocytic infiltrates (Schmid et al., 1994). As 
assessed by Ki-67 staining, it appears that CLL cells actively proliferate in 
“pseudofollicles”, hence the name “proliferation centres” was coined (Burger et al., 
2009).  
It has been established that the neoplastic transformation of CLL cells occurs in the 
lymphoid tissues (Burger et al., 2005) supported by the microenvironment in the LNs 
and BM. However, the histology of lymph nodes or bone marrow in CLL is 
heterogeneous, and the relationship between different histological patterns and the 
disease progression has been insufficiently studied, partially, perhaps due to the scarce 
availability of the resources such as tissue biopsies and BM aspirates which are not 
necessary for CLL diagnosis or prognosis. Yet better insight into the complex 
interactions between CLL cells and tissue microenvironment is paramount to our 
understanding of CLL aetiology, epidemiology and prognostication, as well as for the 
development of the novel therapeutic approaches.  
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As stated above, CD180, as a member of the toll-like receptor family, is a 
microenvironmental sensor, with complex signaling patterns, closely associated with 
BCR signaling. Our group has previously shown that CD180 is expressed on 
approximately 60% of CLL samples, although the density of the expression reflected in 
the antibody binding sites/cell was lesser than that on control B cells (Porakishvili et al., 
2005). However, these studies were restricted to CLL cells circulating in the peripheral 
blood. It was essential to assess expression of CD180 on CLL cells in lymphoid tissues 
implicating possible role of microenvironment through a putative endogenous ligand. 
Here analysis of the results of a collaborative study with the St Bartholomew’s Cancer 
Institute, Queen Mary University of London, of CD180 expression on 3 normal tonsillar 
and 63 paraffin CLL LN tissue sections, under the supervision of Dr Sergey Krysov, 
performed by Mr Andrew Clear, an expert technician, together with the team of 
researchers and students from UoW were shown and discussed.    
5.2 Results 
Since this was the first attempt to visualize CD180 expression in paraffin tissue 
sections, primrily titration of anti-CD180 rabbit polyclonal antibody (Sigma Aldrich, UK) 
was performed using three paraffin sections of human tonsils as controls (Figure 5.1).  
The titration identified the optimal dilution of the antibody in PBS - that of 1:150, which 
was further used to stain CLL LN paraffin sections. However, the titration study also 
revealed high level of expression of CD180 on lymphocytes from the mantle zone of 
germinal centres and in interfollicular regions. Since T cells do not express CD180, this 
data is consistent with the intensive expression of CD180 on B cells in normal tonsils. 
The staining of five normal tonsillar sections produced almost identical results (data not 
shown).  
Further application of optimised concentration of anti-CD180 antibody to the paraffin 
sections was performed. Unsurprisingly, the results were highly heterogeneous. There 
was noticibale absence of the germinal centers within these structures. In order to 
analyse the data, scoring system was applied to the sections stained in triplicates. H-
score (or “histo” score) determines the membrane staining intensity (0, 1+, 2+, or 3+) 
for each cell in a fixed field (Hirsh et al., 2003; John et al., 2009) as it is described in 
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Material and Methods. The final H- score ranged from 0 to 300 where 0-1+ intensity of 
staining was considered as low, 2+ as intermediate and 3+ as high (Figure 5.2).  
 
Figure 5.1. Representative profile of immunohistochemical (IHC) staining of paraffin 
sections of normal human tonsils. 2µm thick paraffin embedded sections of the tissues from 
normal tonsils were stained with different dilutions of rabbit anti-CD180 polyclonal antibodies as 
described in the Materials and Methods. 20x magnification (A, C and E); 4x magnification (B, D and F).  
Rabbit anti-CD180 polyclonal antibody dilutions: 1:150 (A and B) 1:500 (C and D) and 1:1000 (E and 











Further attempt was made to find a correlation between the H-scores of the CD180 
staining in CLL lymph node sections with clinical and available (pre-performed on the 
same sections) laboratory data, including prognostic markers and cytogenetic 
abnormalities, where available. The results indicated two statistically significant 
correlations between the H-score of the expression of CD180, the stage of the disease 
(Figure 5.3) and the expression of Ki-67 (Figure 5.4).   
 
Figure 5.2. Representative patterns of CD180 expression in lymph node tissue sections 
from CLL patients. (40x magnification). 2µm CLL lymph node paraffin embedded sections were 
stained with the optimal dilution 1:150 of rabbit anti-CD180 polyclonal antibodies as described in the 
Materials and Methods. The patterns of the expression are based on the scores: 0-1+ (low), 2+ 
(intermediate) and 3+ (high). Arrows indicate positive expression of CD180 (brown). Poorly organized 
structures with absence of germinal centres are visible. The blue line is equal of 50mm. 
 
Expression of CD180 in the lymph nodes was significantly lower (p=0.003) in CLL 
patients at Binet stage B, compared to the Binet stage A (Figure 5.3). Unfortunately, 
the number of the patients at Binet stage C was very low, hence the results regarding 
this stage were inconclusive, although all four Binet stage C patients which were 
assessed showed high levels of CD180 expression in the lymph node sections. 
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Another striking correlation was revealed between the expression of CD180 and Ki-67, 
a cell cycle- associated protein (Figure 5.4). There was a strong direct correlation 
between the H-score of CD180 expression and the expression of Ki-67 (p=0.0003) 
indicating that CD180+ cells in the lymph nodes are the ones that preferably enter cell 
cycle.  
No other statistically significant correlations have been found of the expression of 
CD180 in lymph nodes of CLL patients, and available clinical or laboratory parameters 




Figure 5.3. CD180 expression in the CLL 
lymph node paraffin sections at Binet 
stages A, B and C.  
Lymph node paraffin sections from CLL 
patients at different stages of the disease 
were stained with the optimal dilution 1:150 
of rabbit anti-CD180 polyclonal antibodies 
as described in the Materials and Methods. 
The intensity of CD180 expression was 
assessed using H-score as described in the 
Materials and methods. Here n is the 
number of patients used at each CLL stage. 
A n=37    
B n=17   





Figure 5.4. Correlation between CD180 and Ki-67 expression in the CLL lymph node 
sections. Lymph node paraffin sections from CLL patients were stained with the optimal dilution 1:150 
of rabbit anti-CD180 polyclonal antibodies as described in the Materials and Methods. The intensity of 
CD180 expression was assessed using H-score as described in the Materials and methods. Ki-67 
analysis was pre-performed on the same sections.  
 
5.3 Discussion 
These studies on the CD180 expression in the lymph node sections of CLL patients 
have further improved our understanding of the dynamics of CD180 expression in 
lymphoid organs and tissues.  
Primarily, the data on three tonsillar samples confirmed previous observations that 
CD180 is expressed preferably by the mantle zone B cells (MZB) and to the lesser 
extent by the germinal center (GC) B cells (Miyake et al., 1995; Chaplin et al., 2011; 
Nagai et al., 2012). Since all these studies were carried out on murine splenic B cells, 
to the best of our knowledge this is the first report showing the expression of CD180 in 
















the activated antigen-experienced cells with mutated IGVH genes (Cerruti et al., 2013). 
The somatic hypermutation and B cells clonal expansion takes place in the germinal 
centres before B cells migrate to the marginal zone (Tierens et al., 1999). This is in line 
with previous findings that CD180 is expressed preferentially by the M-CLL cells 
(Porakishvili et al., 2005), e.g. antigen experienced cells which went through the lymph 
node germinal centers (Chiorazzi et al., 2005). Therefore, it could be assumed that 
CD180 is expressed on human B cells after their migration from germinal centres to the 
marginal zone. Indeed, it had been shown that mice splenic MZB cells undergo 
activation, proliferation and antibody secretion upon stimulation with anti-CD180 mAb 
(Chaplin et al., 2011). The data here suggests that CD180 might be considered as a 
biomarker of antigen experienced normal human B cells migrating from GCs to the 
marginal zone of lymph nodes.  
CLL cell architecture in the LNs was entirely different: it was hard to observe distinct 
follicles and extra-follicular regions due to infiltrations of neoplastic malignant cells as 
it had been previously noted (Schmid et al., 1994; Dick et al., 2006).  
Very importantly, there was a highly heterogeneous expression of CD180 in individual 
lymph node sections in CLL, as reported for the peripheral blood by Porakishvili et al. 
(2005). Porakishvili et al., (2005) also showed that individual CLL clones were 
characterized by a stable pattern of CD180 expression during two years of 
observations. Together with results analysis presented in this chapter, this suggests 
that positivity or negativity for CLL expression might represent an intrinsic feature of 
individual CLL clones. However, to confirm this, PB and LN studies should be carried 
out on the same CLL patients. Since LN biopsies are not generally performed now in 
CLL patients, this would be logistically hard to achieve.  
Unlike the peripheral blood (Porakishvili et al., 2005) where no correlation was found 
between the expression of CD180 and the disease stage, the lymph nodes of the 
patients with more advanced disease (Binet stage B) showed a significantly lower 
intensity of CD180 expression, compared to patients at disease stage A (p=0.003)  
(Figure 5.3). Importantly, CD180 expression in CLL lymph nodes directly correlated 
with their entering into the cell cycle as measured by Ki-67 upregulation(p=0.0003) 
(Figure 5.4), indicating that CD180+ could be considered a marker for CLL cells 
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proliferating in the lymph nodes. It had been shown that CLL cells are often organized 
into the proliferation centres (PCs) wherein they undergo malignant transformation, 
survival and expansion as a clone (Schmid et al., 1994; Soma et al., 2006; Ciccone et 
al., 2011). The PC CLL cells generally express phenotypic markers of 
activated/proliferating cells evidenced by higher levels of CD38, Ki-67, ZAP70 and IgM, 
and preferably belong to the U-CLL (Schmid et al., 1994; Soma et al., 2006; Gine et 
al., 2010). It appears therefore that CD180 expression on the LN CLL cells might be 
indicative of the cells organized into the proliferation centers. 
That CD180+ CLL cells express high levels of Ki-67 is in line with the previous studies 
of our group showing that the ligation of CD180 on PB CLL cells leads to their 
proliferation measured by Ki-67 expression (Porakishvili et al., 2011). One can 
hypothesize that on activation and proliferation of CLL cells in the PCs assisted by the 
CD180 receptor interaction with a putative ligand, CD180 would be downregulated from 
CLL cells as it has been shown for B cells in autoimmune diseases (Kikuchi et al., 2008; 
Koarada et al 2014). My own data presented in Chapter 4, also points towards the 
process of receptor endocytosis, hence the lower expression of CD180 might be seen 
in lymph nodes at more advanced Binet stages (Figure 5.3). As for Binet stage C, more 
data is required in order to make a conclusion regarding possible recovery of CD180 
expression in lymph nodes. This study has not been normalized according to the 
applied treatment of CLL patients at more advanced stages of the disease which 
represents an additional factor affecting the results.  
 
5.4 Conclusions 
1. In normal tonsils CD180+ is expressed preferentially on the mantle zone and 
interfollicular B cells.  
2. CD180 is heterogeneously expressed in the lymph nodes of CLL patients with 
patterns varying from low to intermediate and high. 
3. CD180 expression on the lymph node CLL cells positively correlates with the 
expression of Ki-67. 
4. Intensity of the expression of CD180 on the lymph nodes CLL cells is higher in 

























It has been very well documented that microenvironment plays a major role in the 
development and progression of chronic lymphocytic leukaemia (CLL). Soluble and 
cell-bound ligands and receptors in the environment of central and peripheral lymphoid 
tissues and organs drive proliferation, survival and expansion of CLL cells.  Our group 
has shown previously that non-canonical Toll-like receptor (TLR) CD180 strongly 
contributes to the regulation of signaling, expansion and survival of CLL cells. Our initial 
studies have documented that CD180 is expressed heterogeneously on approximately 
60% of CLL cells in the peripheral blood (PB), with a significantly higher level of 
expression on M-CLL, rather than U-CLL samples (Porakishvili et al., 2005). This study 
also confirms the pattern of highly heterogeneous expression of CD180 in the lymph 
node (LN) CLL cells with an H-score ranging from 0 to 300 (Figure 5.2). It would have 
been important to check whether positivity or negativity for CD180 represents an 
intrinsic feature of a given CLL clone in the LNs and in the PB or whether it can be 
modulated during CLL cell trafficking in and out of the LNs. Since currently LN biopsies 
are extremely rare in the process of the CLL patient management, this would be 
logistically hard to explore. On one hand, previous studies by our group have indicated 
that individual CLL samples have stably maintained their CD180 expression profile 
throughout 24 months of observation (Porakishvili et al., 2005). On the other hand, data 
analysis of this study has shown here that CD180 can be rapidly downregulated, in 
vitro, from the CD180+ CLL cells, the process accelerated by the ligation of BCR 
(Figure 4.4). However, this drop in the expression of CD180 might be influenced by the 
removal of CLL cells from their microenvironment or endocytosis of CD180 linked to a 
putative antigen.  
That CD180+ cell samples might be enriched with antigen-experienced CLL cells 
follows from our observations of its expression on MZB cells and on those in 
interfollicular spaces (with less frequency) in normal tonsils (Figure 5.1). In addition, 
some level of correlation between the expression of CD180 and CD38, particularly in 
U-CLL samples (Porakishvili et al., 2005, and Chapter 3) was also noted. Most 
importantly the pilot studies performed in this project have indicated that double 
negative CD180/CD38 CLL cells belong to the prognostically favorable DLEU1 
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genotype (Chapter 3). All this data would argue that CD180 is associated with CLL cells 
undergoing survival, proliferation and expansion.   
However, not all blood CD180+ CLL samples were found to be responsive to 
stimulation. Out of CD180+ CLL samples only half responded to the ligation with anti-
CD180 monoclonal antibody (mAb) by activation, cycling, and reduced basal apoptosis. 
CD180-mediated CLL cell activation and survival was comparable or superior to that 
induced by CD40 ligation or addition of the recombinant IL-4 (Porakishvili et al., 2005). 
CLL samples which responded to CD180 ligation by increased expression of CD86 
(activation) and Ki-67 (cell cycling) were termed responders (R-CLL). In contrast, 
CD180+ CLL samples that failed to respond to anti-CD180 mAb, despite expressing 
CD180 receptors, were termed non-responders (NR-CLL).  
Our group further demonstrated that CD180 ligation on R-CLL cells and normal B cells, 
led to a strong upregulation in the phosphorylation of ZAP70/Syk, ERK, p38MAPK, and 
AKT protein kinases (PK), which was indicative of interaction between or utilization of 
the same signaling pathways by CD180 and BCR (Porakishvili et al., 2011). Thus, the 
hypothesis has been put forward that CD180 as a microenvironmental sensor, 
contributes to or regulates BCR-mediated signaling in response to the (auto) antigen(s). 
R-CLL cells within the microenvironment of lymphoid tissues in the proliferation centers 
(PCs) would have an advantage of receiving survival, proliferation and, as a result, 
expansion signals from both, BCR and CD180. In contrast, CD180-mediated signaling 
in NR CLL cells did not progress from ZAP70/Syk phosphorylation indicating a block in 
activation of downstream protein kinases, and possible anergy (Porakishvili et al., 
2011).  
However, in the same paper it has been noted that although phosphorylation of AKT, 
ERK, and p38MAPK was significantly increased in R-CLL in response to the CD180 
ligation, compared to NR-CLL samples, there was substantial level of heterogeneity in 
the intensity of responses. More data was required to ascertain whether the range in 
the intensity of PK activation is associated with a range of CD180 expression on CLL 
cells in the PB (Porakishvili et al., 2005) and/or lymph nodes (Figure 5.2). In order to 
clarify the CD180-mediated signaling pathways in CLL downstream from ZAP70/Syk, 
CLL samples were recategorized into AKT signalers (AKT-S) and p38MAPK signalers 
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(p38MAPK-S), since these two PKs appear to represent two alternative signaling 
pathways observed in the majority of CLL samples (Porakishvili et al., 2015). Activation 
of both, AKT and p38MAPK was seen in a small cohort of CLL samples and they were 
termed double signalers (DS) whereas the remaining CD180+ CLL samples which did 
not respond to CD180 ligation by activating either of the two pathways were defined as 
non-signalers (NS).  
There is strong evidence as shown in previous publications by Porakishvili et al. to 
suggest that NS CLL cells are anergic, since they responded poorly to other established 
CLL stimuli such as anti-CD40 mAb and rIL-4 (Porakishvili et al., 2011). In addition, 
CD180 expression is higher on M-CLL cells (Porakishvili et al., 2005), and it has been 
well documented that M-CLL cells respond poorly to various stimuli, including anti-IgM 
Ab (Chiorazzi et al., 2005; Stevenson et al., 2011), partially because IgM expression 
on M-CLL cells is low (Porakishvili et al., 2005). However, it is impossible to exclude 
the possibility, that alternative downstream pathways are used by NS cells rather than 
being refractive to the ligation of CD180.  
It was important to follow CD180-mediated signaling through alternatively AKT or 
p38MAPK activation downstream to the apoptosis/survival in order to identify 
physiological consequences of CD180-mediated signaling in CLL. It was found that 
AKT (and associated PI3K)-mediated pathway leads to the CLL cell survival, whilst 
p38MAPK – favoured apoptosis (Porakishvili et al., 2015).  
Since the same PKs are activated as a result of the signal transduction from sIgM it 
was paramount to study the interaction between CD180 and sIgM mediated pathways, 
and how this might have impinged on CLL cell survival. Our group has determined that 
the ligation of sIgM with the stimulatory polyclonal Ab mostly leads to the activation of 
BTK/PI3K/AKT signaling pathway and cell survival. Most importantly though, priming 
of CLL cells with anti-CD180 mAb redirected prosurvival BTK/PI3K/AKT signaling 
mediated through BCR towards pro-apoptotic p38MAPK pathway. Rewiring of 
signaling from pro-survival to pro-apoptotic pathway was not observed in control B cells 
suggesting that the regulatory effect of CD180 ligation on sIgM is unique for CLL cells 
(Porakishvili et al., 2015).  
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As a logical follow up of that study, it was important to investigate, how CD180 signaling 
interacts with the second BCR isoform – sIgD, which was one of the aims of this project. 
The data obtained demonstrated that IgD ligation on CD180+IgD+ CLL cells with 
stimulating polyclonal antibody led mostly to the activation of p38MAPK pathway and 
subsequent apoptosis of CLL cells (Figures 4.1, 4.2 and 4.3). These findings may 
contradict some previous publications (Haerzschel et al., 2016; Sabouri et al., 2016), 
however there are also reports confirming our data (Tavolaro et al., 2013; Hacken et 
al., 2016) In addition our data is skewed towards CD180+IgD+ cells only. This might 
mean that CD180+IgD+ cell subset is enriched with those CLL cells where IgD ligation 
leads predominantly to the apoptosis, compared to the CD180-IgD+ cell subset. Most 
importantly, priming of CLL cells with anti-CD180 mAb led to the concordant activation 
of p38MAPK and increased apoptosis (Figures 4.2 and 4.3). This means that priming 
with CD180 will direct signaling by both BCR isoforms – sIgM and sIgD towards 
activation of p38MAPK and apoptosis of CLL cells (Figure 6.1) thus suggesting new 
therapeutic approaches for the treatment of CLL. 
 
Figure 6.1: Hypothetical scheme of a cross-talk between CD180 and BCR IgM and IgD 
signaling pathways. CD180-mediated pathway can operate via both, pro-survival BTK/PI3K/AKT or 
pro-apoptotic p38MAPK pathway, whilst sIgM-mediated signaling mostly operates through 
BTK/PI3K/AKT, and sIgD – via p38MAPK. Cross-talk between the receptors redirects the signaling 
pathway from BTK/PI3K/AKT to p38MAPK and subsequent apoptosis.  
In the light of molecular therapies with inhibitors of signaling pathways, my data 
regarding BTK activation was indecisive. I have observed a range of the BTK 
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phosphorylation responses through CD180 ligation alone, or in combination with the 
ligation of BCR. In many cases, BTK phosphorylation was seemingly bypassed 
downstream to the AKT. Ibrutinib resistance in some CLL clones and its toxicity has 
been reported and the drug itself does not lead to the apoptosis of CLL cells but rather 
to the accumulation of CLL cells in PB, rather than in the LN and the spleen (Furman 
et al., 2014; Wiestner, 2015). Therfore prior to the treatment with Ibrutinib, Idealisib or 
any other inhibitors of signaling pathways, each CLL case should be tested not only for 
BTK activation upon sIgM engagement, but also a cumulative effect following the 
ligation of sIgM, sIgD and CD180. The additive effect of the ligation of all three 
receptors, in vivo, might downregulate some of the PKs involved in the pro-survival 
signaling in CLL cells making inhibition therapy unnecessary and ineffective, and this 
can be tested, in vitro. In addition, Ibrutinib would have no effect on p38MAPK-S CLL 
cells which do not recruit BTK. 
It is becoming obvious that intraclonal diversity plays an important role in CLL 
progression and outcome. Stratification of these CLL subpopulations is of a paramount 
importance, in order to identify correct targets for personalized therapy. Our group has 
established that the pattern of CD180 expression on CLL cells and signaling pathways 
it utilizes helps to delineate physiological status of these subsets in relation to the 
precision therapy in conjunction with established prognostic indicators such as CD38 
expression and chromosomal aberrations. 
Our findings on the modulation of signaling pathways through CD180 and BCR (sIgM 
and sIgD) and the temporal effects of their ligation is consistent with multiple ligands in 
the, in vivo, microenvironment regulating the survival of CLL cells. Since CD180 can 
alternate inhibition and promotion of the leukemic growth it may impact clinically 
relevant tumour host microenvironment interactions. Although it is clear that BCR 
signals are important for CLL cells survival, my data indicates that involvement of sIgD 
shifts the balance in favour of apoptotic pathways. CLL cell activation via CD180 does 
not abrogate pro-apoptotic activity of sIgD but acts synergistically. This opens avenues 




• Confirmation of hypothesised co-localization of IgM and CD180 receptors in the 
lipid rafts upon stimulation with anti-CD180, anti-IgM and anti-IgD to assess 
upstream events of the cross-talk of the signaling pathways. 
• Identification of the precise chain of intracellular PKs involved in the dichotomy 
of p38MAPK and AKT-mediated pathways following ligation of CD180. 
• Assessment of the stratification value of CD180 in CLL in conjunction with 
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